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1.1 HIV and AIDS: history and epidemic 
The acquired immunodeficiency syndrome (AIDS) was recognized for the first time as 
a new disease in 1981, when the first clinical cases of AIDS were observed in a 
cluster of men who have sex with men and injecting drug users who presented with 
symptoms of Pneumocystis carinii infection, a rare opportunistic infection known to 
occur in people with a severely compromised immune system (Schliep and Yarrish 
1999). Further symptoms were extensive mucosal candidiasis, cytomegalovirus 
infection and the development of rare malignancies as Kaposi´s sarcoma (Gottlieb et 
al. 1981; Masur et al. 1981). In 1983, a retrovirus, which has later on been named the 
human immunodeficiency virus (HIV), was isolated and declared as the causative 
agent of the disease (Barre-Sinoussi et al. 1983; Gallo et al. 1984). Since its 
discovery, the disease has spread dramatically throughout the world and had 
infected over 38 million people by the year 2005 (UNAIDS 2006). Although the 
introduction of antiretroviral treatment in 1996 (Williams 1997) had led to a significant 
decrease of AIDS-related deaths (UNAIDS 2010), the HIV pandemic continues to be 
a big challenge in public health. In 2012, still 35.3 million people were living with HIV, 
2.6 million new infections were occurring annually and still almost 2 million deaths per 
year were registered (UNAIDS 2013). Treatment still does not reach all affected 
people and even though a lot of prevention efforts have been done throughout the 
world, in some countries the epidemic continues to spread, due to obstacles as 
beliefs, value and education systems, ignorance, poverty, fear of discrimination, no 
access to a developed health care system and political instabilities within countries 
(UNAIDS 2010; UNAIDS 2013).  
1.2 HIV transmission pathway and pathogenesis 
“The HI virus is the causative agent of AIDS and AIDS is the end stage of a 
protracted pathogenic process in which the immune system of an infected person 
and its ability to control infections or malignant proliferative disorders are 




The HI virus is transmitted through blood transfusions (infected blood products) 
contaminated drug injecting needles or shared razor blades, perinatal transmission 
(birth and breastfeeding) and unprotected sexual intercourse (sperm and vaginal 
secretions)(CDC 1985; Curran 1985). Sexual intercourse is the primary mode of HIV 
infection worldwide, followed by mother to child transmission and in some regions 
injecting drug users (UNAIDS 2007). The HI virus causes progressive immune failure 
by infecting and killing vital cells of the immune system, such as macrophages, 
dendritic cells and in particular CD4 T-helper cells, which are responsible for the cell-
mediated immune response. A decline of the CD4 T-helper cells below a critical level 
leads to a loss of adequate immune response and the body becomes progressively 
more susceptible to opportunistic infections (Ascher and Sheppard 1988; Levy 1993; 
Douek et al. 2009). Therefore, the measurement of CD4 T cell counts has become an 
important tool in the management and therapy of HIV-infected persons and is a 
criteria included in the CDC classification of HIV/AIDS (CDC 1992). AIDS is only the 
end stage of the progressive destruction of the human immune system, in which the 
host has become unable to defend itself against opportunistic infections (Schüpbach 
1999). 
1.3 HIV/AIDS epidemic in Sub-Saharan Africa 
Nearly 95 % of the people infected with HIV/AIDS live in the developing world and of 
all people infected worldwide, 70 % live in Sub-Saharan Africa. 76% of all deaths 
related to AIDS occur in this region. The main affected group of individuals is those 
who are the most productive socially, reproductively and economically. Extinction of 
this group of people affects the country’s economy and its further development. More 
than half the adults infected with HIV in Africa are women and there is also a high 
incidence of vertical transmission (UNAIDS 2013). The high incidence of infectious 
diseases (malaria, tuberculosis and others), poverty, malnutrition and limited access 
to health care worsens the situation of the HIV epidemic in Africa. HIV/AIDS remains 
one of the top leading causes of death in this region of the world (UNAIDS 2007). 
Main cause of AIDS death are the opportunistic infections (UNAIDS 2007). An 
opportunistic infection is defined as an infection which is caused by a microorganism 
normally non-pathogenic in healthy hosts, which acts as a pathogen under certain 




infection (Symmers 1965). One of the most common opportunistic infections in 
HIV/AIDS is oral candidiasis (OC) (Scully et al. 1991; Samaranayake et al. 2002).  
1.4 The importance of oral lesions in people living in Sub-
Saharan Africa 
Early detection, monitoring and treatment of individuals infected with HIV, besides 
prevention and information campaigns, is an important task in the fight against the 
HIV epidemic and the fatal consequences that the progress of this disease may have 
on a country.  
As resources and diagnostic tools in Sub-Saharan Africa are very scarce, the 
inspection of the oral cavity often remains the only (and an important) detection tool 
of a possible HIV infection, noting that HIV infection and AIDS are highly associated 
with several oral lesions (Wanzala et al. 1989). One of them, OC, is still reported to 
be strongly associated with the HIV infection in Africa and also remains the most 
common oral lesions associated with HIV around the world (Damtie et al. 2013; 
Kumar et al. 2013; Naidu et al. 2013). It may be more severe in African than in similar 
patients in Western Europe (Enwonwu 1994; Curtis et al. 2012; De Beaudrap et al. 
2013) and significantly impair the nutrition and quality of life of the HIV-infected 
people, leading to malnutrition and rapid disease progression (Hodgson and 
Rachanis 2002). This emphasizes the importance of the early detection of these oral 
lesions to improve the morbidity associated by offering appropriate treatment and 
reduce the fatal consequences of the progress and continuous spread of the disease.  
With the advent of the antiretrovirals, in places where this treatment has been 
introduced, rates of OC and AIDS-related deaths have been reported to decrease 
(Nkuize et al. 2010; De Beaudrap et al. 2013; Meless et al. 2014), potentially 
signalizing an improvement of the immune system under this regimen. But in many 
African countries the treatment coverage of patients in need of antiretrovirals 
remained for long insufficient; in many countries below 20%, which accounts for only 
one quarter of the people living with HIV in Sub-Saharan Africa that had access to 
antiretroviral treatment in the year 2006 (UNAIDS 2006). Therefore OC remains 
highly prevalent among HIV-infected individuals in Africa (Kamiru and Naidoo 2002; 
Damtie et al. 2013; Okoje et al. 2013) and an important tool in the diagnostic and 
management of the disease (Ranganathan et al. 2004), as in most cases it can be 




HIV disease status, progression and eventual treatment failure (Greenspan 1997; 
Coogan et al. 2005). 
1.5. Oral candidiasis  
1.5.1 Oral candidiasis and HIV 
OC, also known as “thrush” (Macher 1988), was included in the first descriptions of 
the acquired immune deficiency syndrome (AIDS) (Gottlieb et al. 1981; Klein et al. 
1984; Fisher-Hoch and Hutwagner 1995), a state of disease caused by the HIV 
(Macher 1988). It is a common opportunistic infection in patients who suffer from this 
disease and one of the first clinical signs of a deteriorating immune system (Scully et 
al. 1991; Samaranayake et al. 2002). Therefore it has been included as a 
"symptomatic condition" highly associated with HIV infection in the CDC and WHO 
classification of HIV/AIDS (CDC 1992; WHO 2007); but it also affects patients with 
other immune disorders, patients undergoing chemotherapy against cancer 
(Baixench et al. 2008) or taking immunosuppressive drugs to protect transplanted 
organs, as well as sometimes healthy subjects (Gupta et al. 1994; Fisher-Hoch and 
Hutwagner 1995; Patterson 1999; Redding et al. 1999; Dongari-Bagtzoglou et al. 
2009; Lopez-Pintor et al. 2013). Nevertheless it is more commonly seen in HIV-
infected individuals and there seems to be a high association between the presence 
of the HIV and eventually the viral load, and appearance of OC (Schuman et al. 
1998; Gottfredsson et al. 1999; Mercante et al. 2006; Fidel 2011; Cassone and 
Cauda 2012). OC is as well an indicator of severe immunosuppression (Klein et al. 
1984; Schuman et al. 1998), correlating with CD4 T cell counts <200 CD4 T cells/μl 
(Mercante et al. 2006; Witzel et al. 2008). Infected individuals with the symptoms of 
OC progress more rapidly to AIDS and death than those without (Greenspan 1997). 
In a study of Lindan et al. (Lindan et al. 1992) in Kigali, Rwanda, the presence of a 
clinically detectable candidiasis in a known HIV-positive female was associated with 
a 40% risk of death within two years. Early recognition and treatment of these lesions 
are therefore very important in the management of HIV-infected patients.  
1.5.2 Diagnosis of oral candidiasis 
The diagnosis of OC has been based on the presumptive criteria set by the EC-




widely used classification in clinical and epidemiological studies (EC-Clearinghouse 
1993; Patton et al. 2013). According to this classification, there are two different 
clinical types of OC that are distinguished: the pseudomembranous candidiasis (PC) 
which is the most usual form (Leao et al. 2009), described as "white or yellow spots 
or plaques" which may have thick creamy, curd-like appearance, "that may be 
located in any part of the oral cavity and can be wiped off to reveal an erythematous 
surface which may bleed" (EC-Clearinghouse 1993; Thompson et al. 2010). The 
second type is the erythematous candidiasis (EC) described as "red areas located on 
the palate or the dorsum of the tongue". Both types belong to the category of "lesions 
highly associated with HIV" (EC-Clearinghouse 1993). But there are also various 
other different clinical presentation forms of OC known as: angular cheillitis (AC), 
median rhomboid glossitis (MRG), atrophic, nodular, plaque-like or hyperplastic 
candidiasis (Lalla et al. 2010; Tarcin 2011). All these forms may also be seen, but 
less frequent, although MRG and AC have been cited by Gazzard and Smith as well 
to be common in HIV-infected people (Gazzard and Smith 1990). Anyhow, these 
other forms are not included in the ECC classification. Several attempts have been 
made to classify these forms beginning with Lehner in 1964, who distinguished 
between acute and chronic forms and ending with a revised classification of Lehner 
by Axell et al. in 1997 (Axell et al. 1997; Parihar 2011). This last classification better 
considers the different clinical subdivision and unusual variants of OC.  
It needs a trained and experienced medical personal to recognize and to distinguish 
between these different presentation forms. Sometimes these different forms may 
present as combinations (EC-Clearinghouse 1993) and some, like the atrophic form, 
occur in earlier stages and may frequently be missed or more difficult to diagnose 
(Gazzard and Smith 1990). OC may be quite often asymptomatic or accompanied by 
symptoms as cotton taste, dysgeusia or burning; it can furthermore spread to the 
esophagus (Tavitian et al. 1986; Gupta et al. 1994; Ally et al. 2001; Nishimura et al. 
2013) and cause swallowing pain, or to other organs, which is associated with a high 
mortality rate (Gudlaugsson et al. 2003; Gautam et al. 2010). Systemic infection in 





1.5.3 Causative agent of oral candidiasis 
The causative agent of OC is yeast fungi from the genus Candida. The yeast species 
Candida is a harmless commensal of the human which may colonize skin and 
mucous membranes like the gastrointestinal or urogenital tract. It is found in the oral 
flora of 15-60 % of healthy individuals (Sanchez-Vargas et al. 2005a; Yang et al. 
2011). It causes infection when there is a disturbance in the host’s specific (humoral) 
and non-specific (cellular) defense systems and virulence genes of the normally 
commensal Candida are activated (Cannon et al. 1995; Sturtevant 2000; Cassone 
and Cauda 2012). It may then cause superficial infection of the skin or mucous 
membranes or penetrate into deeper tissue layers, and disseminate in the blood 
system and organs causing candidemia (Pfaller and Diekema 2007).  
More than 200 species of Candida are known today, but only few are pathogenic to 
humans. Out of these, Candida albicans (C. albicans) has been described to be the 
main pathogen of oral and systemic candidiasis and remains until date the main 
pathogen in this context (Thompson et al. 2010). However, other non-C. albicans 
yeast species (spp.) like C. glabrata, Issatchenkia orientalis (I. orientalis/ C. krusei), 
C. tropicalis are increasingly being described to cause infection and they are 
becoming of increased importance as they show patterns of antifungal resistance to 
azoles, the antifungals still used as first line treatment (Krcmery and Barnes 2002; 
Snydman 2003; Nadagir et al. 2008; Bassetti et al. 2009; Pappas et al. 2009). 
Especially patients with extensive exposure to antifungals or recurrent OC as it is in 
patients with advanced stages of AIDS are affected (Patel et al. 2006; Nadagir et al. 
2008). A relatively new species closely related to C. albicans identified is C. 
dubliniensis. C. dubliniensis has been mainly recovered from the oral cavity of HIV-
infected individuals and AIDS patients in association with OC (Sullivan et al. 1995; 
Coleman et al. 1997; Loreto et al. 2010). This species seems to be linked to HIV 
infection and may also be resistant to Fluconazole (Moran et al. 1997; Nadagir et al. 
2008; Scheid et al. 2012). It is therefore important to be aware of the emerging new 
pathogens in this context. This rise in Candida species other than C. albicans and the 
continuous incidence of resistant species makes the management of the infection 
more and more difficult. Species determination and susceptibility testing should 




This is a problem in settings where further diagnostic facilities to determine and 
differentiate species and perform resistance analysis are not available.  
1.6 Chad 






Figure 1: Map of Chad and landscape impressions. A. Map of Chad (from: 
http://www.loc.gov/item/91681423/, accessed 20.03.15). B. northern arid and C. southern 
tropical region. The clinic of Maingara, where the study took place was located in the 
southern tropical part of the country. 
Chad is a land-locked country located in north central Africa measuring 1,284,000 
square kilometers. In the language of the Buduma (an ethnic group who inhabits 
Lake Chad) it is called “big water” which refers to the Lake Chad, the second largest 
lake in West Africa and one of the most important wetlands on the African continent 
(Room 2008). It is enclosed by its neighbors: Libya in the north, Sudan in the east, 
Central African Republic in the south, Cameroon and Nigeria in the south-west and 
Niger in the north-west (Figure 1A). The population counts 11,193,452 inhabitants, of 
which most concentrate in the tropical south part of the country where the picture of 
wet savanna with an annual rainfall of 600-1200 mm/year dominates. The northern 









(Figure 1B+C). The temperature varies between 13°C to 29°C in January and 25°C to 
44°C in May in the northern part and between 15°C and 34°C in January and 23°C 
and 35°C in May in the southern part of the country (LCBC 2013). 
Ndjamena is the capital with 808,000 inhabitants located at the west border of the 
country. The next biggest cities are Moundou, Sarh and Doba which are mainly 
concentrated in the south. Sarh is the third biggest city of Chad after Ndjamena and 
Moundou with around 100,000 inhabitants (http://www.geoba.se/population.php?cc= 
TD, accessed 19.06.14). The average population is very young with a median age of 
16.9 years. 47% are under the age of 15 and only 2.9% are above 65. Till 2010, the 
life expectancy was 46 (WHO 2010). 
80% of the Chadians live in rural areas from agriculture (although only 4% of the 
country´s land is arable) and subsistence economy. It is one of the poorest countries 
in the world [Ranking 184 of 186 in the Human development Index (HDI)] (UNDP 
2013). The geographical circumstances influence the differences in the socio-
economic living styles. In the northern part of the country the population is largely 
nomadic. They have some livestock with mostly small ruminants and camels. In the 
southern part the population is more settled.  
Chad has more than 200 different ethnic groups and more than 120 different 
languages and dialects. The biggest group is the Sara (27.7%) settled in the 
southern part of the country which speaks Sara. Further 26% of the population 
speaks Arabic, one of the official languages of Chad. The other official language is 
French. The illiteracy rate is high: 76% among women and 55% among men 
(UNESCO 2012). 
The majority of the population is Muslim (approx. 55%) of which most live in the 
northern part of the country and speak Arabic. Further 35% are Christian and are 
more concentrated in the southern part of the country. The rest belongs to traditional 
African religions (animist, 7%) and others (CIA 2014). 
1.6.2 History and politics 
Chad became colonized in 1920 by the French and acquired its independence in 
1960. Since, it has been marked by political instability with several civil wars and 




south. The Darfur crisis in the neighboring Sudan which started in 2003 also affected 
the nation’s instability with hundreds and thousands of refugees cumulating at the 
Chadian border. Despite all Mr. Idriss Deby who became president in 1990 managed 
to stay in power until today (Prunier 2008; BBC 2015). 
1.6.3 Health care system 
The health care system in Chad is marginally developed and insufficient to provide 
the necessary health care needed. Only 30% of the population has access to the 
health care system (WHO 2010). The physician density is 0.04 per 1,000 inhabitants 
which are concentrated in the urban areas and the existing hospitals are only 
rudimentarily equipped. In this context especially in the rural area, traditional healing 
methods are being favored. The situation is worsened by the political conflicts in 
Darfur, Sudan and Central African Republic which have led to a refugee’s movement 
especially in the southern-east part of the country. Furthermore food crisis, missing 
sanitation and water sources affect the country´s development and economy. 
1.6.4 Chad and HIV 
In Chad, the HIV prevalence was about 3.3% in 2007 and 2.7% in 2012 (UNAIDS 
2007 ; CNLS 2012; UNAIDS 2013). The distribution is inhomogeneous within the 
country with a prevalence of 2.3 % in the rural and 7% in the urban area (UNGASS 
2008). In the region of Sarh, the HIV prevalence of pregnant women was about 4% in 
2012, and among sexual workers the prevalence was highest with 20% (CNLS 
2012). The main transmission pathway remains the heterosexual unprotected 
intercourse (including paid sex) and the vertical transmission pathway from mother to 
child and breastfeeding. As in the overall region, women are more affected than men; 
in Chad 4% compared to 2.6% within the same age group. In Chad this is particularly 
due to polygamy (UNGASS 2008). 
The HIV prevalence is not yet as high as in other African countries, but multiple 
factors promote the spreading of the disease. These include poverty, religious and 
cultural taboos, ignorance and lack of knowledge about the modes of transmission of 
the disease ongoing with high prevalence of unprotected sex, illiteracy of women, sex 
workers, high prevalence of sexually transmitted diseases, a rudimentary insufficient 




the neighboring countries Sudan and Central African Republic which lead to a rising 
number of refugees at the south and south-eastern borders of Chad. In some regions 
it is reported that the prevalence may be as high as 10% (UNAIDS 2009; CNLS 
2012). 
A lot of efforts are being done to elucidate the population and projects for the 
prevention of the transmission of the disease, detection and a close follow-up of the 
infected individuals are being established (UNGASS 2008; CNLS 2012). The creation 
of the "Centre de Santé de Maingara" in Sarh, Chad in 2004 was part of one of those 
projects. 
1.6.5 The clinic of Maingara in Sarh 
Maingara is a city district of Sarh. The clinic (Figure 2), in which we found a 
collaboration partner to conduct our study, was founded with the support of the 
BELACD (Bureau d´Études et de Liaison des Actions Caritatives et de 
Développement) of Sarh, a non-governmental national aid organization, and could 
open its activities in 2004 to offer counseling, HIV testing, treatment and follow-up for 
HIV-infected individuals.  
  
Figure 2: The clinic of Maingara  
At the time of the study Dr. Lydia Kersch from Germany was the leading head of the 




nurses, two social workers, three trained assistants for lab diagnostics and a 
secretary for patients’ registration and file establishment. There was a section for HIV 
screening and counseling with social attendance, a day clinic equipped with an 
ultrasound and ECG machine, a lab with a microscope, photometer, and a CD4 T cell 
counting machine. Since August 2005 it had furthermore been supplemented with 18 
beds to receive and treat severely ill cases.  
Due to the educational and awareness training especially among the analphabetic 
youth, schools and young couples in the surrounding villages of the parish and the 
installment of institutions able to receive and to take care of affected people, the 
number of people presenting for a screening test rose constantly and a decline in HIV 
seropositivity of the tested persons could be observed from 2004 to 2006 (42% to 
18.5%) (Dr. L. Kersch personal communication). 
By the year 2006 the clinic was taking care of 1279 affected individuals (18% of the 
patients screened in Maingara) which were followed regularly at monthly intervals. 
82% of the examined patients were in the reproductive age of 12 to 45 and 627 
(49%) were under antiretroviral treatment at that time. Of these, 89.4% had been 
followed regularly, 11% went out of sight and 7 % went elsewhere.  
By 2007, 71.3% of the patients were under antiretroviral treatment. Female patients 
were in the majority (60%) and also in the majority put under antiretroviral treatment. 
Still, the mortality rate in 2006 was high with 28.1% for the hospitalized patients and 
15% for all the followed patients (Dr. L. Kersch personal communication). 
Only a basic selection of drugs was available to treat and prevent the most common 
AIDS-related opportunistic diseases and diagnostic relied mainly on the clinician’s 
subjective clinical impression. Antifungals were available in a very limited amount and 
therefore rarely prescribed. 
1.6.6 HAART at the clinic of Maingara 
The antiretroviral treatment available at the center was the highly active antiretroviral 
treatment (HAART) regimen. It is a combination of three antiretrovirals which was 
given according to the National Guidelines of Chad for antiretroviral therapy which 




the parish of Sarh and its international and private donors. Patients of the day clinic 
also had to provide a small contribution of about 3000 Francs CFA (approx. 4.60€) in 
quarterly payments. As the government did not yet provide antiretrovirals for free until 
the year 2007, patients had to contribute partially to the treatment costs (5000 Francs 
CFA/approx. 7.60€ per month). In case of inability to pay, the medication was given 
on credit when already started. To avoid HAART interruption, the patients were 
informed about the danger and consequences of an interruption always in the 
presence of a family member and had to oblige themselves in written form to take the 
medication as prescribed and take a responsible behavior towards others before the 
start of the treatment. Furthermore medical records were established and social 
workers looked up for the patients under HAART in their homes if they did not appear 
to their regular control. Nevertheless, 8.2% had an interruption of more than 45 days 
(Dr. L. Kersch personal communication).  
1.7. Aim of the study  
In Chad, no data on the prevalence of OC or oral colonization with Candida species 
in HIV-infected and healthy subjects were available. Neither there was known which 
kind of Candida species colonize the oral cavity of the Chadian population or cause 
infection in HIV-immuno-compromised patients and if they are susceptible to the 
existing antifungals. The clinical importance of OC in association with HIV in Chad 
was therefore unclear. 
The first aim of the study was to determine the type of the existing yeasts colonizing 
the oral cavity of the Chadian healthy and HIV-infected population and test their 
sensitivity to five common antifungals in use (Amphotericin B, Nystatin, Fluconazole, 
Itraconazole and Caspofungin) with the goal to give a picture of the current situation 
and eventually improve the management of the oral fungal burden of HIV/AIDS 
patients in that specific country. Furthermore we wanted to define the prevalence of 
OC in the HIV-infected and healthy population, and analyze the influence and 
association of other factors like age, sex, HAART and antimicrobial therapy and CD4 




2. Material and methods 
 
2.1 Materials 
2.1.1 Machines and instruments  
Autoclave, steam sterilizer                                                                               unknown 
AXIMA Assurance™ platform                                    Shimadzu Biotech, Duisburg, DE 
Bruker MALDI Biotyper 2.0®                                                       Daltonics, Bremen, DE 
CD4 counter, cyFlow®                                                                                                      Partec, Münster, DE 
Centrifuge, type 5417R                                                          Eppendorf, Hamburg, DE 
Dynex Revelation microplate reader                         Dynex Technologies, Virginia, US 
Incubator, type BB 6220 CU Heraeus®    Thermo Fisher Scientific, Langenselbold, DE  
Microscope                                                                                            Zeiss, Jena, DE 
Multichannel pipet, Multipette®-Plus                                       Eppendorf, Hamburg, DE 
pH-meter, HI 221                                                  HANNA Instruments, Vöhringen, DE 
Photometer, Mac Farland®                                                                BioMérieux, Marcy, FR 
Pipets “Reference”, type 4810; 
0,5-10 μl; 10-100 μl; 50-200 μl; 100-1000 μl                          Eppendorf, Hamburg, DE 
Pipet pump, Pipetus®-Akku                                                 Hirschmann, Eberstadt, DE 




Saramis MALDI Biotyper®                                                   AnagnosTec, Potsdam, DE 
Sterile bench    BDK Luft- und Reinraumtechnik GmbH, Sonnenbuehl-Genkingen, DE 
Vortex REAX-top                                                                  Heidolph, Schwabach, DE 
Weighing machine type BL 310                                               Sartorius, Göttingen, DE 
2.1.2 Single-use material 
 
Cryobank system                                                         Mast Diagnostica, Reinfeld, DE  
Eppendorf tubes 0,5 ml safe-lock                                          Eppendorf, Hamburg, DE  
Eppendorf tubes 2,0 ml safe-lock                                          Eppendorf, Hamburg, DE 
Flat bottom microdilution plates, 96 wells                          Greiner, Kremsmünster, DE 
Glas test tubes, round bottom                                                        Roth, Karlsruhe, DE 
Glas test tubes, flat bottom                                                             Roth, Karlsruhe, DE  
Graduated glas pipets 10 ml, 20 ml, 50 ml                                   Brand, Wertheim, DE 
Graduated cylinder 1000 ml                                                           Roth, Karlsruhe, DE 
HIV testkits ImmunoComb®/ Determine®                                        Orgenics, Yavne, IL 
Inoculating loop white 1 μl                                                     Sarstedt, Nürmbrecht, DE  
Microscope slides and square cover glass                           Knittel, Braunschweig, DE 




Pipet tips, yellow, 200 μl                                                         Sarstedt, Nümbrecht, DE 
Plastic test tubes 50 ml with cap                                            Sarstedt, Nümbrecht, DE 
QIAamp DNA MIni Kit                                                                      Qiagen, Hilden, DE 
Rice agar                                                                                            Oxoid, Wesel, DE  
Sterile agar gel transport swabs                                                       Copan, Brescia, IT 
Sterile Combitips 5 ml                                                            Eppendorf, Hamburg, DE 
Sterile cotton swabs                                                                         Copan, Brescia, IT 
Sterile-Filter Corning® 0,22 μm (cellulose-acetate)     Corning GmbH, Wiesbaden, DE 
Sterile Plastic Petri Dish 90mm ø with cover                     Greiner, Kremsmünster, DE 
2.1.3 Addings and chemicals  
 
Agar (for STAIB-Agar)                                                                 Merck, Darmstadt, DE 
Antibiotic Medium 3, AM3                             Becton Dickinson GmbH, Heidelberg, DE 
Α-D(+)-Glucose-Monohydrate                                                       Roth, Karlsruhe, DE 
Creatinine (for STAIB-Agar)                                                        Merck, Darmstadt, DE 
Dimethyl Sulfoxide, DMSO, Hybri-Max®                                      Sigma-Aldrich, Steinheim, DE 
Glucose                                                                                          Roth, Karlsruhe, DE 




KH2PO4, (for STAIB-Agar)                                                          Merck, Darmstadt, DE  
Natrium chloride NaCl                                                                 Merck, Darmstadt, DE 
3-(N-morpholino) propansulfonic acid, MOPS                Sigma-Aldrich, Steinheim, DE 
Sabouraud powder medium                                                        Merck, Darmstadt, DE 




Gentamicin (Merck,  
Darmstadt, DE)        
     Stock 
    
  
     16 mg/ml 
         Final 
concentration  
      







      










Amphotericin B                                                                         Sigma, Taufkirchen, DE 
Caspofungin                                                                               MSD GmbH, Haar, DE 
Fluconazole                                            Discovery Fine Chemicals, Bournemouth, UK 
Itraconazole                                            Discovery Fine Chemicals, Bournemouth, UK 
Nystatin                                                                           Sigma, Taufkirchen, DE
17 
 
2.1.4 Recipes for culture mediums 
 
AM3 17.5 g/l AM3 
 3 g/l glucose       
  
RPMI 10.4 g/l RPMI 
 34.53 g/l MOPS 
 2 g/l glucose 
  
Sabouraud agar 65 g/l Sabouraud 
 1 ml Chloramphenicol (16mg/ml) 
 1 ml Gentamicin (16mg/ml) 
  
Staib-Agar: 5 % pulverized Guizotia abyssinicia seed 
 0.1 % glucose 
 0.1 % KH2PO4 
 0.1 % creatinine 
 1.5 % agar 
2.1.5 Patients 
Confirmed HIV-positive (HIV+) and -negative (HIV-) patients were recruited from the 
medical centre of Maingara in Sarh, Chad. As the majority of patients consulting at 
the clinic in Maingara were HIV-positive, a group of patients in a small dispensary   





2.2 Methods and study procedure 
2.2.1 Ethics commission 
Before realization, the research proposal was presented and approved by the ethics 
commission of the Georg-August-University of Göttingen (Application-N° 21/06/07) 
and the participating institutions in Chad (see appendix). All patients involved in the 
study were orally informed about the aim of the study and asked for their agreement 
before implementation according to the Helsinki Declaration (WMA 2013). 
2.2.2 Patient acquisition 
All patients who presented for consultation at the clinic of Maingara in Sarh during the 
study period where orally informed (for the majority could not read or write) about the 
aim of the study (see appendix). Only those who gave their informed oral consent 
were included into the study, irrespectively of their age or sex. The majority was HIV-
infected and came to their regular monthly health control, or had just been tested 
HIV-positive. To establish a control group, a group of patients had been seen in the 
“dispensary” (small health center) of Bemouli, in a rural area 50 km away from Sarh, 
a small health care point providing basic health attendance by a nurse for a normal 
population. Confirmed HIV-negative patients who presented at the clinic of Maingara 
were as well included. 
2.2.3 History taking and clinical inspection/examination 
After informing the patient about the study and getting his/her agreement, 
informations on the medical history, age, sex, HIV status, current opportunistic 
infections and medications, HAART, and the last CD4 T cell count were noted or 
taken from medical records. A brief clinical examination was done, the oral cavity 
inspected at day light additionally with a small torch and the observations noted. 
From patients presenting again during the study period, a consecutive sample and 
examination was taken to evaluate disease progression and effect of antimycotics or 




2.2.4 HIV testing 
The HIV status of the patients was determined by a rapid test (Determine® HIV-1/2), 
and if positive it was confirmed through another rapid test kit (ImmunoComb® II 
HIV 1&2 Bispot). If both were positive, the patient was considered HIV-positive. 
2.2.5 HAART  
The antiretroviral therapy available in Chad was TRIOMUNE 30® for patients with a 
body weight under 60 kg and TRIOMUNE 40® for patients above 60 kg. TRIOMUNE 
is a combination of two nucleosid reverse transcriptase Inhibitors (NRTIs) Stavudine 
(30 or 40 mg), Lamivudine (150 mg) and one non-nucleosid reverse transcriptase 
inhibitor (NNRTI) Nevirapine (200 mg). The daily treatment regimen consisted of one 
tablet twice a day (WHOPAR 2011; NAM 2014) Patients received treatment 
according to the National Guidelines of Chad for antiretroviral therapy which had 
been based on the WHO Standards (WHO 2006). It was indicated when the patient 
had a CD4 T cell count <200 CD4 T cells/µl or was in a WHO clinical stage III or IV. 
Patients with a WHO clinical stage II could also get the therapy when CD4 T cells 
were between 200 and 350 CD4 T cells/µl (Table 1). In case of intolerability of 
Nevirapine or tuberculosis treatment with Rifampicin, patients received a combination 
with Efavirenz (NNTRI) and in very few cases of suspected therapy failure or Kaposi 
sarcoma, the protease inhibitor (PI) Indinavir was given. 
 
Table 1: Indication for HAART according to the National Guidelines of Chad 
 
WHO 
clinical stage I 
WHO       
clinical stage II 
WHO       
clinical stage III 
WHO           
clinical stage IV 
CD4 T cells     
≥ 350 no HAART no HAART HAART possible HAART 
200-350 no HAART HAART possible HAART HAART 





 2.2.6 Swabs 
The oral cavity of the patients was sampled by taking swabs with a sterile cotton 
swab from visible oral lesions or when no visible symptoms, going over tongue, 
palate and side cheek pockets. Each swab was directly inoculated onto 1/8th of a 
Sabouraud (SAB) agar plate (Figure 3). Due to the lack of an incubator the plates 
were cultured over night at room temperature (approximately between 26°C and 28 
°C at night time and 30-36°C at day time) in the time from April to June. The plates 
were controlled for the growth of yeasts after 24 and 48 hours. If positive, the number 
of colony-forming units (CFU) was counted. A culture counting from 1 to 15 CFU was 
considered as “low fungal burden” (LFB) and a counting from above 15 CFU or 
confluent growth on a 1/8th surface of the plate as “high fungal burden” (HFB). 
Samples of several colonies from each morphologically distinct appearance were 
stored on slant agar at 4°C until they were transferred to Germany, were they were 
recultivated and separated for further analysis. The samples were collected over a 
period of time of 3 months, between April and June 2007.  
 
Figure 3: Growth of yeast on the agar plates from the direct smear of the patients. On 
each plate there was space for eight swab specimens. CFU were counted by hand. In the 
right picture confluent growth with mixed species. 
 
2.2.7 Differentiation (Germany) 
All collected samples were recultivated in Germany on Sabouraud agar. Swabs 
which presented apparent mixed cultures by colony morphology were separated and 
purified before differentiation. After verification and identification of yeasts under the 




with cultivation on different culture mediums, like rice and Staib agar, API 
differentiation kits, and in case of difficult identification polymerase chain reaction 
(PCR). Additionally, all samples were identified with two commercially available 
MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time Of Flight) 
identification systems: Bruker MALDI Biotyper 2.0 and AnagnosTec Saramis. Before 
use, all samples were cultivated over night at 37°C and in case of slow-growing 
organisms over two to three days. 
2.2.7.1 Microbiological and biochemical differentiation 
2.2.7.1.1 Microscopy 
All isolated species were first identified as yeasts under the microscope by staining 
with methylene blue. Specimens with several colonies with distinct morphology were 
separated and purified before further differentiation process (Figure 4). 
.               
         A. Microscopic image of yeasts    B. Mixed culture (on SAB agar)   C. Purified culture (on SAB agar) 
 
Figure 4: Images of yeasts and yeast culture. A.Typical ellipsoid shape of living yeasts 
stained with methylene blue under the microscope (X1000). B.Growth of two morphologically 
distinct yeasts (C. albicans (opaque) and I. orientalis (dull) on SAB agar. C.Purified yeast 
culture (P. fabianii) with visible colonies. 
2.2.7.1.2 Rice agar, Staib agar and API  
All species identified as yeasts were cultivated on rice-tween agar covered with a 
glass slide (semi-anaerobic conditions) at 26.5 °C for 48 h and checked for the 
growth of chlamydospores and pseudomycelium under the microscope (Figure 5). 
The isolates with visible growth of chlamydospores were again cultivated in the same 
way on Staib agar to differentiate between C. albicans and C. dubliniensis (Staib and 
Morschhauser 1999; Loreto et al. 2010). All the other isolates were differentiated with 
the API system (API 32 C and API 20 C AUX) and in case of difficult identification a 






Figure 5: Chlamydospore formation by C. albicans on rice-tween agar. Induced 
pseudomycelium and chlamydospores formation by C. albicans on rice-tween agar. 
2.2.7.1.3 PCR 
For the samples that could not be identified by the biochemical standard methods, a 
PCR was performed to amplify the ITS2 rDNA region followed by sequencing of the 
PCR product (Chen et al. 2000). Fungal DNA from a single large colony was isolated 
with the QIAamp DNA Mini Kit. The ITS2 rDNA region was amplified and the product 
sequenced (SeqLab, Göttingen, Germany) and identified in the CBS yeast sequence 
database (http://www.cbs.knaw.nl/, accessed 20.05.14). 
2.2.7.2 Differentiation with the MALDI-TOF  
For the confirmation of the species identification, two MALDI-TOF systems were 
available for an evaluation period and the strains were included into that study (Bader 
et al. 2011). 
2.2.7.2.1 Bruker MALDI Biotyper 2.0 system  
For yeast identification (Bader et al. 2011) with the MALDI BioTyper 2.0 system 
(Figure 6), cells of approximately five colonies from Sabouraud agar plates were 
suspended in 300 µl water and inactivated by addition of 900 µl 96 % ethanol. The 
cells were spun down and the pellet air dried at room temperature, resuspended in 
50 µl 70 % formic acid and extracted by addition of an equal volume of acetonitrile 
and thorough mixing. Cellular debris were removed by centrifugation (17,000×g for 2 
min), 1 µl of the clear supernatant was spotted onto a polished steel carrier (Figure 
6), allowed to dry, overlaid with 1 µl of HCCA matrix (saturated solution of α-cyano-4-
hydroxycinnamic acid in 50 % acetonitrile, 2.5 % trifluoroacetic acid, Bruker 
Daltonics) and allowed to dry again. The matrix could be stored for a maximum of two 




Measurement was done with the MALDI BioTyper 2.0 (library version 3.0) and 
FlexControl software on a Microflex LT20 mass spectrometer (20 Hz nitrogen laser), 
using a bacterial test standard (Bruker Daltonics) as a molecular weight standard. 
Spectra were detected in positive linear mode, mass range 2 – 20 kDa. Intensity of 
the laser was controlled by the FlexControl software driven in automatic mode, at the 
settings recommended by the manufacturer. Only species identifications with scores 
>2.000 were accepted, but proposed identifications at the genus level only were 
rejected. 
2.2.7.2.2 AnagnosTec Saramis system 
For yeast identification (Bader et al. 2011) with the Saramis system (“Spectral 
Archive and Microbial Identification System”), cells from a single colony on a 
Sabouraud agar plate were directly applied onto the steel carrier, dried for a short 
time (~2 min) and lysed by suspension in 0.5 µl 25 % formic acid. The sample was 
allowed to air dry at room temperature, overlaid with 1 µl HCCA matrix (saturated 
solution of α-cyano-4-hydroxycinnamic acid in acetonitrile:ethanol:water 1:1:1 
acidified with 3% v/v trifluoroacetic acid) (AnagnosTec) and again allowed to air dry. 
Measurement was done on an AXIMA Assurance™ platform in positive linear mode, 
mass range 2 – 20 kDa, using E. coli strain CCUG 10979 as a molecular weight 
standard. Intensity of the 50 Hz nitrogen laser was under control of the acquisition 
software, at the settings recommended by the manufacturer. Only hits within the 
Superspectra database (Saramis™ Premium, version 3.3.1) with scores >80 % were 






Polished steel carrier Bruker MALDI Biotyper 2.0 system 
  
Figure 6: MALDI Biotyper 2.0 system  
 
2.2.8 Antifungal susceptibility testing 
Antifungal susceptibility testing of the isolates obtained in this study was done 
according to the NCCLS reference method for broth dilution antifungal susceptibility 
testing of yeast; Approved Standard, M27-A2 (Guidelines of the Clinical and 
Laboratory Standard Institute, CLSI) (NCCLS 2002). The antifungals tested were 
Fluconazole, Itraconazole, Nystatin, Amphotericin B and Caspofungin. 
2.2.8.1 Broth mediums and preparation of the microdilution plates 
The broth microdilution test was performed in sterile microdilution plates with 96 flat 
bottom wells (Greiner). The broth mediums used were RPMI 1640 buffered with 
morpholinepropanesulfonic acid (MOPS) to a pH of 7.0 at room temperature (21.3°C) 
and AM3 (Antibiotic Medium 3). The RPMI 1640 medium was being used for the 
testing of Caspofungin and the azoles and the AM3 medium for the testing of 
Amphotericin B and Nystatin. Amphotericin B, Nystatin and Itraconazole were 
dissolved in dimethyl sulfoxide (DMSO), Fluconazole in methanol and Caspofungin in 




adapted for each antifungal agent according to the MIC (minimal inhibiting 
concentration) ranges described in the NCCLS protocol (0.063 - 1.5 μg/ml for 
Amphotericin B, 0.016 - 24 μg/ml for Nystatin, 0.016 - 16 μg/ml for Caspofungin and 
Itraconazole, and 0.250 - 256 μg/ml for Fluconazole). 100 μl of medium with the 
highest drug concentration was dispensed into the wells of column 1, column 11 
contained the lowest concentration and column 12 served as the positive growth 
control, containing 100 μl of a sterile drug-free medium. The trays were stored at 
-70°C and thawed one hour before use.  
2.2.8.2 Inoculum stock suspension: 
The inoculum used was prepared from colonies cultured for 24 h under aerobic 
conditions at 37°C, which were suspended in sterile saline (NaCl). The turbidity was 
adjusted with a spectrophotometer to a value of 0.5 McFarland.  
2.2.8.3 Working suspension and dispersion onto the plates: 
The final working suspension was prepared by diluting 1:100 in physiological NaCl 
followed by a 1:20 dilution in RPMI 1640 medium for Caspofungin and the azoles and 
in AM3 medium for Nystatin and Amphotericin B. The inoculum had 5x102 to 2,5x103 
cells per ml. 
The wells were dispensed with 100 μl of the prepared inoculum suspensions with a 
multichannel pipette, starting with the positive control well going downwards in the 
row. For the quality control of the plates, the strains recommended by CLSI (C. 
parapsilosis (ATCC 22019) and I. orientalis (ATCC 6258) were included in the testing 
procedure.  
2.2.8.4 Incubation and reading of the results 
The plates were incubated in a humid box at 36-37°C and analyzed after 48 hours for 
the presence or absence of visible growth with the help of a reading mirror. The 
growth of each well was compared to the growth control well and noted down as 
visible growth, low visible growth, no growth or contamination. Furthermore, the cells 
in each well were resuspended with a pipette and the optical density at 60 nm (OD 
600) measured with a microplate spectrophotometer. The results were then 
compared with the results of the visual reading to evaluate and control the plausibility 




B and Nystatin was defined as the lowest concentration in which at least 90 % of 
growth of the sample was inhibited, defined as MIC90, for Caspofungin and the 
azoles, as the lowest concentration in which at least 50 % of growth was inhibited 
(MIC50).  
To minimize deviation, each organism was tested 2 to 4 times and the average MIC 
was calculated. An isolate was considered resistant if the average MIC was greater 
than their respective CLSI clinical breakpoints (≥ 64 μg/ml for Fluconazole, ≥ 1 μg/ml 
for Amphotericin B and Itraconazole). For Nystatin and Caspofungin no clinical 
breakpoints have yet been defined.  
2.2.9 Storage 
All isolates were stored in a Cryobank (Mast Diagnostica®) - System at -70 °C. 
2.2.10 Statistics 
Statistical significance was calculated using Student’s T-test for quantitative 
variables, Chi-Square test for percentages and for small samples sizes the Fisher´s 






3.1 Patient cohort 
3.1.1 Distribution according to age and gender 
A total number of 589 patients were seen during the study period. The age 
distribution was between two and 70 years, whereas the majority of the patients was 
between 19 and 35 years old (n=263). The average age was 34 in Maingara and 28 
in Bemouli. Children below 12 years of age were represented in Maingara with 1.2% 
(n=5) and 2.0% (n=3) in Bemouli. From the five children in Maingara, two were HIV-
positive and three HIV-negative. Seven patients were above the age of 60: three 
from Maingara, out of which one patient was HIV-positive. For a small fraction of 
patients the exact age remained unknown. In all age groups, female patients were 
dominant. In total, the distribution consisted of 73.5% (n=433) female and 26.5% 



























Figure 7: Distribution of the patients according to their age and gender in the general 





3.1.2 Distribution of the patients according to their HIV status 
From the total number of 589 patients consulted, 441 were from the clinic in 
Maingara and 148 from the medical dispensary (health center) in the village of 
Bemouli. From the cohort consulted in Maingara, 384 (87.1%) patients were HIV-
positive. The patients for the control group of HIV-negative patients were recruited 
from Maingara (27.8%; n=57) and Bemouli (72.2%; n=148). 
For the majority, patients recruited from Bemouli remained untested. HIV testing had 
not been performed among these patients, due to ethical considerations, as the 
medical dispensary was a small normal health care point providing basic health 
attendance by a nurse for a normal population. HIV prevalence in rural areas of Chad 
was very low and affected individuals or severe ill cases used to directly go to the 
specialized centers or hospitals in the urban area (CNLS 2012). The cohort of 
patients from Bemouli was therefore presumed to be HIV-negative. In the eleven 
cases of the patients where yeast growth was observed, HIV testing was performed, 
after their informed consent. All were confirmed to be HIV-negative, supporting the 
assumption that this clientele could be used as an additional HIV-negative control 
group. Furthermore clinical oral impression was without suspicious peculiarities. 
Patients from Bemouli were therefore considered HIV-negative for the purpose of this 
study and as there were no relevant significant differences between the HIV-negative 
patients from Maingara and Bemouli, these patients were combined into one group.  
3.1.3 Gender distribution in the different subgroups 
As in the overall cohort, in the HIV-positive and HIV-negative group female patients 
were most represented with 75 % (n=287) in the HIV-positive and 71% (n=146) in the 














































n= 205 n= 384 n= 589
 
Figure 8: Distribution of the gender in the different subgroups. HIV-positive patients 
were recruited only from the clinic in Maingara, HIV-negative individuals mainly from 
Bemouli. Female patients were significantly more represented than male patients in all 
subgroups. HIV+= HIV-positive; HIV-= HIV-negative; n= number of patients. 
 
3.2 Prevalence of fungal colonization 
In a first step, we analyzed to what degree the different patient subgroups (HIV-
positive with and without HAART, HIV-negative control) were colonized with oral 
yeasts. For this analysis only samplings from the first visit of each patient were 
analyzed and categorized. Patients who had received antifungal or antibacterial 
treatment within the last three weeks before and at time of the first sampling were 
fully excluded from this evaluation and patients having received less than 25 days of 
HAART were excluded from the HAART+ group. (In a separate chapter (3.11) 
patients with antibacterial but without antifungal treatment will be included again for 
the analysis of the influence antibacterial treatment on oral colonization). After 
implementing all exclusion criteria, a total of 534 patients were included for further 
analysis: 343 HIV-positive, 56 HIV-negative from Maingara and 135 HIV-negative 
from Bemouli. 52.5% (n=180) of the HIV-positive patients were under HAART. The 
age and gender distribution in the HIV-positive subgroups were similar to the HIV-




A total of 130 swabs from the 534 patients included in the study were yeast-positive 
(=24.4%) at the patients´ first visit. There was no significant difference in oral yeast 
colonization between the different subgroups: HIV-positive patients only had a 
slightly higher prevalence of oral yeast colonization (25.4%) than HIV-negative 
patients (22.5%). There was also no significant difference between the HIV-negative 
patients from Maingara and Bemouli (data not shown). 
HIV-positive patients were therefore further divided into two subgroups: “with 
HAART" (HAART+) for those who had received HAART for at least 25 days and 
“without HAART" (HAART-) for the patients, who were without HAART at the time of 
and prior to examination. Here we found a significant difference between HAART 
treated and HAART non-treated patients: HIV+/HAART+ patients had a significantly 
(p=0.003) lower colonization rate (18.9%; n=34) than HIV+/HAART- patients (32.7%; 
n=53), but not (p=0.111) as compared to the HIV-negative control (22.5%; n=31) 




















































Figure 9: Prevalence of yeast growth in the oral cavity in the different subgroups. 
HIV+/HAART+ patients had a significant lower colonization rate than HIV+/HAART- patients, 






3.3 Degree of oral fungal burden in HIV-negative and 
-positive patients 
A semi-quantitative analysis of the degree of fungal burden based on CFU counts on 
the agar plate of the positive oral swabs between the study group and the control 
group revealed no significant difference (p=0.7). The rate of high fungal burden (HFB; 
CFU>16 on a 1/8th agar plate) was 32.2% for the HIV-positive and 35% for the HIV-
negative patients (Figure 10). In contrast, within the HIV-positive subgroups, patients 
receiving HAART had a significantly (p=0.02) lower prevalence of HFB (18%, n=6) 
than those without HAART (42%; n=22), but not significantly lower than the controls 









































Figure 10: Prevalence of low and high fungal burden in the positive oral swab. There 
was a significant difference in oral fungal burden between HIV+/HAART+ and HIV+/HAART- 
patient. HIV+/HAART+ patients had a significantly (p=0.02) lower rate of high fungal burden 
(18%) than HIV+/HAART- patients (42%). n= number of patients, LFB= low fungal burden= 
colonization with 1-15 CFU/1/8th of an agar plate, HFB= high fungal burden= colonization 




3.4 Classification of oral symptoms and diagnosis of oral 
candidiasis 
Diagnosis of OC was more challenging than expected, as the typical clinical 
presentation of OC ("whitish plaque which can be whipped off easily revealing 
erythematous area beneath") (EC-Clearinghouse 1993) was rare. Subsequently, we 
therefore based our diagnostic and classification criteria on those proposed by 
Lehner (Lehner 1964; Parihar 2011) who classified OC based on clinical, 
mycological, histological, serological and therapeutic criteria. As additional tests such 
as exfoliative cytology or tissue biopsy for confirmation or rejection of OC were not 
available on site and antimycotics were rare, we classified our patients only 
according to the clinical observations and the result of the culture from the oral swab. 
Based on the symptoms observed and additionally inspired by the scoring index for 
oral mucositis proposed by McGuire et al. (2002) patients were first subdivided into 
the three following subgroups: 
 noS = asymptomatic: no visible alterations in the oral cavity 
 mS  = mild symptoms: whitish or yellowish coated tongue with <50% 
affected area (Figure 11A+B). 
 sS   = severe symptoms: one of the following symptoms or the 
combination of them: thick whitish or yellowish coated tongue with 
>50% affected area and/or atrophy and/or erythema and/or other 






C-E:  severe symptoms
>50% coated tongue Median rhomboid glossitis 
with central atrophy




Figure 11: Examples of classified symptomatic patients. Patients classified with "mild 
symptoms" only had a tongue coating affecting <50% of the tongue (A+B); patients with 
"severe symptoms" a thick white or yellowish coating affecting >50% of the tongue area (C), 




Together with the results from mycological culture (yeast negative vs. yeast positive), 
four different patient groups were defined (Table 2): 
 Yeast- :  all patients with absence of yeast (irrespectively of symptoms) 
= non-carriers  
 YnoS   : Yeast positive patients with no symptoms 
= asymptomatic yeast carriers 
 YmS    : Yeast positive patients with mild symptoms 
= yeast carriers with mild symptoms 
 YsS     : Yeast positive patients with severe symptoms 
= yeast carriers with severe symptoms 
 
Only patients from group YsS will further be discussed and classified as patients with 
oral candidiasis (Table 2).  
 
Table 2: Classification of the patients including clinical presentation and oral swab 
culture 





















According to the symptoms observed and the result of the oral swab, four different clinical 




3.5 Prevalence of symptoms and oral yeast colonization in 
the different symptomatic groups 
 
3.5.1 Prevalence of symptoms 
HIV-positive patients were significantly more often symptomatic than the controls 
(p=0.03). The respective prevalence of symptoms in HIV-positive patients was 40% 
and 30% in HIV-negative patients. There was no significant difference in the 
prevalence of symptoms between HIV+/HAART- (44%) and HIV+/HAART+ (36%) 
patients (p=0.13), but a significant difference in the prevalence of severe symptoms 
(HIV+/HAART-: 26% and HIV+/HAART+: 12%; p≤0.01). HIV+/HAART- patients also 
had a significantly higher prevalence of severe symptoms (26%) than the controls 
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Figure 12: Prevalence of symptomatic patients in the different subgroups. 
HIV+/HAART- patients were significantly more often symptomatic than the controls (p≤0.01) 
and had significantly more severe symptoms than HIV+/HAART+ patients (*= p≤0.01) and 





3.5.2 Prevalence of yeasts in the oral cavity of asymptomatic 
patients  
Asymptomatic HIV-negative and HIV-positive patients were in up to 80% of the cases 
yeast-free and there was no significant difference (p=0.09) in the prevalence of oral 
yeast carriage in the HIV-positive subgroups (Figure 13).  
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Figure 13: Prevalence of yeast in the oral cavity of asymptomatic patients. 
Asymptomatic HIV-negative and HIV-positive patients were mainly (in up to approximately 
80% of the cases) free of yeast colonization. n= number of patients 
 
3.5.3. Prevalence of yeasts in the oral cavity of symptomatic 
patients  
In HIV-positive patients the severity level of symptoms significantly correlated with 
the presence or absence of yeasts in the oral cavity (p≤0.01 for HIV+/HAART- and 
p=0.05 for HIV+/HAART+ patients). The oral cavity of patients with mild symptoms 
was in 83% (HAART-) and 81% (HAART+) of the cases yeast-free and up to 60% 
(HAART-) and 41% (HAART+) of the patients with severe symptoms where yeast-
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Figure 14: Prevalence of yeast in the oral cavity in symptomatic patients. Mild 
symptoms in HIV-positive patients were more associated with the absence of yeasts in the 
oral cavity and severe symptoms significantly correlated with the presence of oral yeast 
colonization in HIV+/HAART- (*= p≤0.01) and HIV+/HAART+ patients (**= p=0.05). A. 
patients with mild symptoms, B. patients with severe symptoms; yeast-= yeast-negative; 




3.6 Association between oral fungal burden and symptoms 
in the different subgroups 
 
In all subgroups, asymptomatic yeast carriers (YnoS) mainly had a low fungal 
burden. In HIV-negative patients there was a higher prevalence of high fungal burden 
in patients with mild to severe symptoms (YmS and YsS). HIV+/HAART+ 
symptomatic patients had the lowest prevalence of high fungal burden and only in 
HIV+/HAART- patients high oral fungal burden was significantly associated with 
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Figure 15: Prevalence of high oral fungal burden according to symptoms in the 
different subgroups. A high oral fungal burden was significantly associated with severe 
symptoms in HIV+/HAART- patients (*= p≤0.01). In HIV+/HAART+ patients this association 
was not obvious. YnoS= yeast positive/no symptoms; YmS= yeast positive/mild symptoms; 




3.7 Prevalence of oral candidiasis in the different 
subgroups 
 
For the patients classified with mild symptoms, the only symptoms noted were a 
mildly coated tongue (<50% of the area). Swab cultures showed a low prevalence of 
yeast colonization (Figure 14A) and colonized patients from that group (YmS) only 
had a low fungal burden (Figure 15). It is therefore highly probable, that these 
patients were only colonized with Candida, so that a classification into any form of 
OC was not undertaken in this group, but rather classified as "colonized patients". 
Only yeast-positive patients with severe symptoms (YsS) were classified as patients 
with oral candidiasis. The prevalence of OC was highest in the HIV+/HAART- group 
with 16% and was reduced in the HIV+/HAART+ group to 5%, which was similar to 
the one in the HIV-negative group (4%). The prevalence of asymptomatic yeast-
carriers (YnoS) was the same in HIV+/HAART- patients as in HIV-negative patients 



































































Figure 16: Prevalence of oral candidiasis. Yeast-positive patients with severe symptoms 
(YsS) were considered as patients with oral candidiasis (OC) and were significantly more 
prevalent in the HIV+/HAART- group with 16% (*= p≤0.01). ø= yeast-negative patients; 
YnoS= asymptomatic yeast-carriers; YmS= yeast-carriers with mild symptoms; YsS= yeast-




3.8 Prevalence of the different forms of oral candidiasis in 
HIV-positive patients 
Only yeast-carriers with severe symptoms (group YsS), as defined above in 3.4 and 
3.7, were further considered and discussed for the diagnosis of OC. In this group, we 
observed different clinical presentations among our HIV-positive patients, which we 
classified according to the classification proposed by Axell et al. (Axell et al. 1997; 
Parihar 2011) (Table 3). 
Table 3: Classification of oral candidiasis by Axell et al. 
Primary oral candidosis ( Group I )                                Secondary oral candidoses ( Group II ) 














Median rhomboid glossitis 
 







Oral manifestations of Systemic 
mucocutaneous candidosis (due to 
diseases such as thymic aplasia and 
candidosis endocrinopathy syndrome) 
This table represents the revised classification of oral candidiasis by Axell et al. (Axell et al. 
1997; Parihar 2011) on which we based our definition and classification of OC. 
The majority of these patients presented with a coated (whitish) tongue affecting 
>50% of the area (48.6%; n=17/35) in HAART- as well as in HAART+ patients (Table 
4). However, the white lesions where not easily removable in our patients and had no 
visible signs of inflamed erythematous area beneath. Therefore these cases were not 
classified as acute pseudomembranous candidiasis (PC). The chronic "plaque-like" 




lesions superinfected with Candida as hairy leukoplakia or lychen planus were also 
taken into consideration. Due to lack of further investigations such as tissue biopsy or 
data about the onset of the symptoms this could, however, not be confirmed. As 
these variants were also clinically less likely, patients with the symptoms of white 
lesions as described above were classified as nonspecific OC. 
The second most common clinical sign was the median rhomboid glossitis (MRG) 
(Figure 11D): white plaque on the tongue with central atrophy or erythematous area. 
Its prevalence was 25.7% (n=9/35). Nearly all of these cases appeared in the 
HIV+/HAART- group (n=8/9) and the median CD4 T cell count was 200 CD4 T 
cells/µl (Table 4). Furthermore, we had 5 cases (14.2%) of clinically diagnosable 
acute pseudomembranous candidiasis with additionally affected palate. These 
patients had a median CD4 T cell count <120 CD4 T cells/µl. Two cases had 
combined oral lesions (PC with MRG and PC with atrophy); their CD4 cell counts 
were <60 CD4 T cells/µl and two cases solely tongue atrophy (lingual papillary 
atrophy). The median CD4 T cell count of the latest was 338 CD4 T cells/µl. 
 






















31.5% 149 17.1% 126 48.6% 
Acute PC 8.6% 115 5.7% 60* 14.3% 
MRG 22.9% 200 2.8% n.d 25.7% 
Atrophy 5.7% 338 0 - 5.7% 
Mixture 5.7% 51 0 - 5.7% 
Total 74.3% (n=26)  25.7% (n=9)  100% (n=35) 
The majority presented with a coated whitish tongue affecting >50% of the tongues´ surface 
classified as nonspecific OC. Second most frequent clinical presentation was the MRG, 
mainly in HIV+/HAART- patients. Acute PC= acute pseudomembranous candidiasis; MRG= 
median rhomboid glossitis; mixture= combination of acute PC with atrophy or MRG; n.d= not 





Except for the patients with symptoms of papillary tongue atrophy, all patients from 
group YsS (with OC) had a median CD4 T cell count ≤200 CD4 T cells/µl (Table 4 
and Figure 17), reinforcing and supporting the diagnosis of OC in that group.  
HIV-positive patients with severe symptoms who were yeast-negative had a median 
CD4 T cell count >250 CD4 T cells/μl (Figure 17) and the correlation between the 
absence of yeasts in the oral cavity of these patients and CD4 T cell counts >250 
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Figure 17: CD4 T cell count and clinical subtypes of oral candidiasis in HIV-positive 
patients. Patients with OC had a median CD4 T cell count ≤200 CD4 T cells/µl, except for 
those with papillary tongue atrophy. In cases of OC-like lesions but no presence of oral yeast 
growth, median CD4 T cell count was always >250 CD4 T cells/µl. - = yeast-negative, + = 
yeast-positive; nonspecific OC= nonspecific oral candidiasis, aPC= acute 
pseudomembranous candidiasis, MRG= median rhomboid glossitis, atrophy= papillary 
tongue atrophy, mix= combination of aPC with atrophy or MRG; horizontal bars indicate 




3.9 Oral colonization and age 
There was no correlation or significance between age and colonization with yeasts in 
the different subgroups (Figure 18), although the median age of colonized HIV-
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Figure 18: Age-dependent oral yeast colonization. In the control group median age of 
patients with oral yeast growth was sligthly higher than those without yeasts. In HIV-positive 
patients no significant differences were observed. ø= yeast- . Horizontal bars indicate median 
age. 
 
If we looked at the different age groups in the different subgroups (Figure 19), in HIV-
negative, as well as in HIV+/HAART- patients, the prevalence of oral yeast 
colonization was highest in the age group of 36-45. In the HIV+/HAART+ group the 
prevalence was highest in the 19-25 age group and decreased with higher age which 
correlates with a longer time on HAART for the 19-45 years old. With increasing age, 
the patients of that group had an increased average of days of HAART: 19-25 (323 

















11-18 19-25 26-35 36-45 46-60















11-18 19-25 26-35 36-45 46-60













11-18 19-25 26-35 36-45 46-60






























b. HIV+/ HAART- c. HIV+/HAART+  
Figure 19: Prevalence of yeasts in the oral cavity according to age. In HIV- and 
HIV+/HAART- patients the highest prevalence of oral yeast growth was in the age group of 
36-45, whereas in the HIV+/HAART+ group it was in the 19-25 age group. With rising age in 
HIV+/HAART+ patients (which correlated with a longer period of HAART), there was a 





3.10 Oral yeast colonization and fungal burden in HIV-
negative and -positive female and male patients 
There was no significant gender-dependent difference in the prevalence of oral yeast 
colonization in HIV-positive and -negative patients (Figure 20A). Although, yeast-
positive male subjects had a higher oral fungal burden than female subjects in both 
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Figure 20: Prevalence of oral yeast colonization and fungal burden in HIV-negative and 
-positive female and male patients. In HIV-negative and HIV-positive patients there were 
no significant differences in the prevalence of oral yeast colonization between male and 
female. But in the HIV-negative group male patients had a significant higher oral fungal 
burden than female patients (*= p=0.01). n= number of patients; F= Female, M= Male; yeast-




3.11 Influence of antibiotics on oral colonization and 
infection with yeasts 
We also analyzed the impact of antibiotics on fungal burden in the oral cavity among 
our patients. For this we excluded those patients which had taken antifungals at the 
time of or in the last three weeks before examination. Only drugs with antibacterial 
effectiveness at time of the first visit or in the last three weeks before were 
considered. Five different classes of antibiotics were in use: Co-trimoxazole, β-lactam 
antibiotics (Penicillin, Amoxicillin, Cloxacillin, Ampicillin), Ciprofloxacin, Metronidazole 
and Doxycyclin. Co-trimoxazole and β-lactam antibiotics were the most frequently 
prescribed. HIV+/HAART- patients more frequently received an antibiotic treatment. 
In total 26 (7.0%) out of 369 HIV-positive and 13 (8.8%) out of 148 HIV-negative 
patients had received an antibacterial treatment. Of these 26 HIV-positive patients, 
nine (34.6%) had a positive yeast culture, out of which eight (89%) where from the 
HIV+/HAART- group, and 17 (65.4%) had no presence of yeast growth. Although 
HIV+/HAART- patients were more frequently yeast-positive, in the different patients 
group there were no significant differences in the prevalence of oral colonization 
between patients with and without antibiotic treatment (p=1.0 (HIV-); p=0.3 
(HIV+/HAART-) and p=0.65 (HIV+/HAART+) (Table 5). 
Table 5: Prevalence of oral yeast colonization with and without antibiotics 
HIV- HIV+/HAART- HIV+/HAART+
no AB AB no AB AB no AB AB
Yeast- 77% 77% 67% 56% 81% 87.%
Yeast + 23% 23% 33% 44% 19% 13%
Significance p=1.0 p=0.3 p=0.65
  
HIV+/HAART- patients were more likely to be colonized with yeasts than HIV- or 
HIV+/HAART+ patients, but in general treatment with antibiotics had no significant influence 




3.12 Prevalence and distribution of yeast species 
In total, 156 yeast isolates from 166 positive oral swabs of the HIV-positive and -
negative patients were differentiated. 17 samples, due to longer storage, could not be 
recovered but 7 out of these could be differentiated by PCR. 
In total, 171 yeasts were isolated and differentiated from the 156 yeast isolates. In all 
patient groups, C. albicans was the most prevalent species: 44.2% in HIV-negative 
(56.3% in the Maingara and 37.0% in the Bemouli HIV-negative groups; data not 
shown) 58.6% in HIV+/HAART+ and 87.1% in HIV+/HAART- patients (Figure 21). 
The HIV+/HAART+ and the HIV-negative patients had a significantly lower 
prevalence of C. albicans and a larger variety of non-C. albicans yeasts than the 
HIV+/HAART- patients (p≤0.01). 
The next most prevalent yeast species were I. orientalis (12.1%; n=7) followed by C. 
tropicalis (8.6%; n=5) and Saccharomyces cerevisiae (S. cerevisiae) (6.9%; n=4) in 
the HIV+/ HAART+ group and C. tropicalis (4.3%; n=3) followed by S. cerevisiae 
(2.9%; n=2) in the HIV+/ HAART- group. In the combined HIV-negative group the 
second next most prevalent species was S. cerevisiae (14%; n=6) (Figure 21). 
Although, in the HIV-negative patients from Maingara C. glabrata was the second 
most frequent species. Among the HIV-negative subjects from Bemouli, no C. 
glabrata was found; instead, S. cerevisiae (18.5%; n=5) and Pichia fabianii (P. 
fabianii) (14.8%; n=4) were the next most prevalent species (data not shown). 
Other isolated species in the HIV-positive group were: C. parapsilosis, C. 
orthopsilosis, P. fabianii, P. farinosa (= C. cacaoi), P. guilliermondii, C. kefyr and C. 
rugosa. A C. orthopsilosis-like species together with C. tropicalis was isolated from 
the oral cavity of a HIV-positive patient undergoing HAART. In the HIV-negative 
groups further isolated species were C. orthopsilosis, C. valida and C. pararugosa. 
C. dubliniensis was not isolated from any of the patients, irrespectively of HIV status. 
Across all subgroups, mixed colonization with ≥ two yeast species was observed: 
seven patients (13.7%) in the HIV+/HAART+ group, three (4.4%) in the 




In the HIV+/HAART- group, mixed colonization always included C. albicans, whereas 
in the HIV+/HAART+ group, mixed colonization predominantly included non-C. 














































Figure 21: Species distribution. The number of patients with mixed colonization was: n=4 
in the HIV- combined, n=3 in the HIV+/HAART- and n=7 in the HIV+/HAART+ group. The 
number of species which were not able to be recultivated from the transported agar slants 
was: n=5 in Bemouli, n=2 in the HIV+/HAART-, n=3 in the HIV+/HAART+ group. C. albicans 
(C.a) was the most prevalent species in all subgroups. HIV- and HIV+/HAART+ patients 




























In HIV+/HAART- patients mixed colonization was always found in combination with C. 



































































F 27 + + n.a. n.d. 
C. albicans  
C. tropicalis 
n.d. 




F 32 + + 60 / 92 54 C. albicans 
C. albicans 
I. orientalis 






+ + 16 / 30 36 C. albicans 
C. albicans 
C. parapsilosis 












F 40 - n.a  n.d C. albicans 
S. cerevisiae 
n.d. 
















3.13 Association of CD4 T cell number with HAART, oral 
fungal burden, symptoms and yeast species  
 
For each HIV-positive patient, the initial CD4 T cell counts were routinely determined. 
Although patients were supposed to have their CD4 T cells regularly counted for the 
follow-up, a current CD4 T cell count was not available for all of the patients in the 
study due to limits in compliance. Therefore, only the subset of patients with recent 
CD4 T cell counts (within the last three months) could be considered for this 
evaluation. 
3.13.1 CD4 T cell counts and oral fungal burden 
Among the patients with an available recent CD4 T cell count (less than 90 days 
before sampling), its relationship with HAART and fungal burden (measured by the 
number of fungal CFU from the direct oral smear) was analyzed. In both HIV-positive 
subgroups the median average CD4 T cell count of the patients with a high fungal 
burden (HFB) was <150 CD4 T cells/μl. In contrast, there was a significant difference 
(p=0.04) in the median CD4 T cell count between HAART-treated and untreated 
patients which only had a low fungal burden (LFB). The median CD4 T cell count was 
214 CD4 T cells/μl in the HIV+/HAART- group as compared to 336 CD4 T cells/μl in 
the HIV+/HAART+ group (Figure 22). For those patients where no yeasts were found 
in the oral cavity, there was no difference between both subgroups. The mean 
average CD4 T cell count was 321 and 313 CD4 T cells/µl in the HIV+/HAART- and 
HIV+/HAART+ groups, respectively. 
The majority of the HIV+/HAART+ patients without yeasts in the oral cavity had been 
under treatment for over one year (median: 520 days). For those patients on HAART 
with low fungal burden, the median time of treatment was 346 days and for those with 
high oral fungal burden 51 days. Therefore, there was a significant quantitative 
reduction of colonizing yeasts depending on the duration of HAART.  
In summary, there was a correlation between low CD4 T cell counts, no or only short 










































Figure 22: Relationship between CD4 T cell counts and fungal burden in HIV-positive 
patients with and without HAART. High fungal burden was associated with CD4 T cell 
counts <200 CD4 T cells/μl in HIV+/HAART- as well as in HIV+/HAART+ patients. ø= no 
fungal growth, LFB= low fungal burden, HFB= high fungal burden. Horizontal bars indicate 
the median CD4 T cell counts per subgroup 
 
3.13.2 CD4 T cell counts in asymptomatic and symptomatic HIV-
positive patients  
There was no significant difference seen in the median CD4 T cell count between 
asymptomatic and symptomatic yeast-negative HIV-positive patients. Median CD4 T 
cell count of yeast-negative HIV-positive patients was 345 and 349 CD4 T cells/µl in 
asymptomatic, 289 and 314 CD4 T cells/µl in patients with mild symptoms and 307 
and 293 CD4 T cells/µl in patients with severe symptoms in the HAART- and 
HAART+ groups, respectively (Figure 23). In both subgroups, asymptomatic and 
symptomatic yeast-carriers with only mild symptoms had a median CD4 T cell count 
>200 CD4 T cells/µl. However, HIV+/HAART+ yeast-carriers without or with only mild 
symptoms had significantly (p=0.02) higher median CD4 T cell counts (432 and 397 
CD4 T cells/µl) than HIV+/HAART- yeast-carriers (212 and 207 CD4 T cells/µl) with 
the same symptoms. Only yeast-positive patients with severe symptoms had a 




associated with CD4 T cell counts <200 CD4 T cells/µl. Nevertheless, 47% (n=8/17) 
of asymptomatic yeast-carriers in the HIV+/HAART- group and 36% (n=4/11) in the 












































median CD4 T-cell count of yeast-negative HIV+ patients
median CD4 T-cell count of yeast-positive  HIV+ patients
median CD4 T-cell count of yeast-positive  HIV+ patients with CD4 T cell count≤200 cells/μl  
Figure 23: Asymptomatic and symptomatic HIV-positive yeast-carriers and their CD4 T 
cell counts. Only yeast-positive patients with severe symptoms had a median CD4 T cell 
counts <200 CD4 T cells/µl in HIV+/HAART- as in HIV+/HAART+ patients. S= symptoms. 
 
3.13.3 CD4 T cell counts, yeast species distribution and fungal 
burden 
C. albicans was the most frequently isolated yeast species in HIV-positive patients 
and associated with a median CD4 T cell count <200 CD4 T cells/µl especially in 
patients with high oral fungal burden (Table 7 and Figure 24). HIV+/HAART+ patients 
were significantly (p≤0.01) more often colonized with non-C. albicans yeast spp. 




count of HIV+/HAART+ patients harboring non-C. albicans yeast spp. was 432 CD4 
T cells/µl and was significantly (p=0.01) higher than patients colonized by C. albicans 
(148 CD4 T cells/µl) in the same group (Table 7).  
 
Table 7: Median CD4 T cell count for C. albicans and non-C. albicans yeast species  
HAART- HAART+
Fungal burden
Low High combined Low High combined
C. albicans 214 140 188 230 104 148
Non-C. 
albicans
125 274 212 409 517 432
Significance p=0.6 p=0.01
 
High oral fungal burden and colonization with C. albicans was associated with CD4 T cell 
counts <200 CD4 T cells/µl irrespectively of HAART. In HIV+/HAART+ patients colonization 
with non-C. albicans yeast spp. was significantly associated with CD4 T cell counts >400 
CD4 T cells/µl (p=0.01). 
 

































There was a significantly higher prevalence (p ≤0.01) of non-C. albicans yeast spp. in the 
HIV+/HAART+ group. Colonization with non-C. albicans yeast spp. in that group was more 











































ø low high 
HAART-




Median CD4 T-cell count of non-C.albicans-colonized patients
Median CD4 T-cell count of C. albicans-colonized patients
Median CD4 T-cell count of patients without fungal burden
C. tropicalis and C. glabrata Other non-C. albicans spp.
 
Figure 24: Species distribution in the oral specimen of HIV-positive patients according 
to their CD4 T cell count and oral fungal burden. Irrespectively of HAART, C. albicans 
was the most frequently isolated species and associated with CD4 T cell counts <200 CD4 T 
cells/µl in patients with a high oral fungal burden. Colonization with non-C. albicans species 
was more frequent in HIV+/HAART+ patients and in the majority of the cases associated with 
CD4 T cell counts >350 CD4 T cells/μl and a low oral fungal burden. Only the non- C. 
albicans species C. tropicalis and C. glabrata were associated with CD4 T cell counts <200 




3.13.4 CD4 T cell counts, yeast species distribution and clinical 
symptoms 
  
There was a high association between severe symptoms, colonization with C. 
albicans and CD4 T cell counts <200 CD4 T cells/µl irrespectively of HAART (Figure 
25A). Almost all patients with severe symptoms harbored C. albicans alone or C. 
albicans combined with a non-C. albicans yeast spp. In contrast, colonization with 
non-C. albicans yeast spp. was more often associated with mild or no symptoms, a 
low fungal burden, as well as with a high CD4 T cell count in HIV+/HAART+ patients 
(Figure 25A+B). Interestingly, colonization with C. glabrata or C. tropicalis was 
associated with CD4 T cell counts <200 CD4 T cells/µl in HIV+/HAART- and 
HIV+/HAART+ patients, but not with severe symptoms (Figure 25). Therefore 
colonization with these species was not associated with OC. There was only one 
case with severe symptoms and high fungal burden with a non-C. albicans yeast spp. 
This patient was without HAART, had a CD4 T cell count of 335 CD4 T cells/µl and 
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Figure 25: Distribution of the species in asymptomatic and symptomatic HIV-positive 
patients. Severe symptoms were highly associated with CD4 T cell counts <200 CD4 T 
cells/µl and colonization with C. albicans irrespectively of HAART (A). Irrespectively of 
symptoms, patients with a high oral fungal burden and colonization with C. albicans mainly 
had CD4 T cell counts <200 CD4 T cells/μl (B). Colonization with non-C. albicans spp. in 
HIV-positive patients was more associated with mild or no symptoms, low fungal burden and 
CD4 T cell counts >200 CD4 T cells/μl, except for the species C. glabrata and C. tropicalis. 




3.13.5 Oral fungal burden, symptoms and species distribution with 
time of HAART  
Division of the patients into subgroups according to their length of HAART showed 
that the prevalence of colonization and symptoms changed over time. It was 
characterized by a general quantitative reduction of yeasts in the oral cavity (Figure 
26A), reduced occurrence of severe symptoms (Figure 26B), as well as reduced 
colonization specifically with C. albicans with a shift towards colonization with non-C. 
albicans yeast spp. correlating with the increase in CD4 T cell number (Figure 27). 
High fungal burden and severe symptoms were highest in HIV-positive patients 
during their first month of therapy and decreased significantly (p=0.01) during the first 
six months of therapy from 36.4% (n=4/11) to 3% (n=1/33). The prevalence of yeast-
positive patients with severe symptoms (=patients with OC) is not completely 
eradicated after this period of time, few cases are still seen even with a treatment 
exceeding this time. Similarly asymptomatic yeast-carriers and patients with high oral 
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Figure 26: Influence of the duration of HAART on oral fungal burden and symptoms. 
There is a diminution in oral fungal burden (A) and symptoms (B) with rising time of HAART 
which was significant in the first six months of HAART (*= p=0.01). yeast-= yeast-negative; 
yeast+= yeast-positive; LFB= low fungal burden; HFB= high fungal burden; noS= no 
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Figure 27: Influence of the duration of HAART on species distribution. There is a shift 
from colonization with C. albicans towards colonization with non-C. albicans yeast spp. with 
time of HAART, correlating with a rise in CD4 T cell number. Colonization with C. tropicalis 
and C. glabrata stayed associated with CD4 T cells <200 CD4 T cells/μl. d= days; m= 




3.14 Efficacy of antimycotic treatment and antifungal drug 
susceptibility testing 
3.14.1 Efficacy of antimycotic therapy 
At time of the first visit or in the last three weeks before, 5 (1.4%) out of 348 HIV-
positive patients were under antimycotic treatment, at second visit 12 out of 134 
(8.9%) and 6 out of 25 (24.0%) at third visit. Patients had received either treatment 
with azoles (oral Fluconazole or Ketoconazole), polyenes (mouthwash with 
Amphotericin B or Nystatin), or topical Clotrimazole, which was administrated when 
patients presented with dermatomycoses and/or oral thrush. 
We analyzed the effect of antifungal treatment and HAART on oral fungal burden as 
well as on the oral clinical symptoms. A patient was considered to respond to 
treatment when there was an improvement in oral fungal burden (from yeast-positive 
to yeast-negative, or from HFB to LFB) and/or in symptoms (symptomatic to 
asymptomatic or severe to mild symptoms). The reverse cases were considered mild 
(yeast-negative to LFB or asymptomatic to mild symptoms) or severe worsening 
(HFB or severe symptoms) of the condition, respectively, and thus treatment failure. 
All colonized HIV+/HAART- patients treated with only an antifungal (n=11) responded 
with clearance of oral yeast or reduction in oral fungal burden (Figure 28A). Further 
two HIV+/HAART+ with severe symptoms and a high fungal burden (CD4 T cell 
counts were <200 cells∙µl-1) were treated with an antifungal and were cured (with no 
presence of yeast) (Figure 28). 
In patients with no therapy at all the oral fungal burden got severely worse in 12% 
(n=6/52) of the cases, stayed unchanged in 69% (n=36/52) of the cases and in 12% 
(n=6/52) there was an improvement with clearance of yeast in the oral cavity. 
HIV+/HAART+ patients showed almost the same outcome (Figure 28A). Although, 
the majority of the cases with unchanged oral fungal burden were patients with no 
fungal burden. 
The analysis of the symptomatic outcome showed similar results except for the 
observed patients treated only with an antimycotic. There only 33 % (n=5/15) had a 
clinically visible improvement of symptoms under antifungal treatment (Figure 28B). 




treatment. Anyhow, in six out of these seven cases there was an improvement in 
fungal burden with clearance of yeast. Antifungal treatment was therefore very 
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Figure 28: Effect of HAART and antimycotic therapy on oral fungal burden. Oral fungal 
burden clearly improved under antimycotic treatment (A). All yeast-positive patients 
responded to solely antimycotic treatment with clearance of yeast, but not always with 
clinically visible change of symptoms (B). The majority of the patients with unchanged oral 
fungal burden (A) were yeast non-carriers. Severely worse= shift from yeast-negative or LFB 
to HFB (A), or asymptomatic or mild symptoms to severe symptoms (B); mildly worse= 
yeast-negative to LFB (A), or asymptomatic to mild symptoms (B). 
 
A species shift under antimycotic treatment could neither be seen in HIV+/HAART+ 
nor in HIV+/HAART- patients (data not shown). Nevertheless, a shift from C. albicans 
or a mixed culture with C. albicans towards colonization with only non-C. albicans 
yeast spp. was seen in four (out of nine colonized) HIV+/HAART+ patients without 
any antifungal treatment (data not shown). 
If we looked at the efficacy of antifungal treatment focusing on patients with OC, 
there was a statistically significant difference between treated and non-treated 
patients (p≤0.01). Patients with OC profited from HAART, antifungal therapy or the 













1 3 (75%) 8 (100%) 2 (100%)
No improvement
5 (83.3%) 1 0 0
Total 6 4 8 2
Significance p≤0.01
 
Oral fungal burden of patients with OC was significantly improved in treated patients with 
HAART, antimycotic or the combination of both (Fisher´s exact test p≤0.01). 
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3.14.2 In vitro antifungal susceptibility of the isolated yeast species 
 
To determine the susceptibility towards common antifungal substances, all yeast 
strains isolated were tested according to the NCCLS Reference Method for Broth 
Dilution Antifungal Susceptibility Testing of Yeast, Approved Standard M27-A2. 
Substances tested were Amphotericin B, Nystatin, Fluconazole, Itraconazole, and 
Caspofungin. Yeast species were considered resistant when their MICs were above 
the clinical breakpoints set by the clinical laboratory standard Institute (CLSI). All 
isolates in this study were susceptible to Amphotericin B with MIC ranges between 
0.031 - 0.5 μg/ml. C. albicans had mainly MICs of 0.125 - 0.250 μg/ml. All C. albicans 
isolates were fully susceptible to Fluconazole and Itraconazole. 15 I. orientalis 
isolates (79.0%) were resistant to Fluconazole, eleven with a MIC of 64 μg/ml and 
four with a MIC of 96 μg/ml. All the other non- C. albicans species were fully 
susceptible to Fluconazole. The nine isolated C. glabrata were fully resistant to 
Itraconazole, with MICs of mainly 2 μg/ml. 17 (89.5%) out of 19 isolated I. orientalis, 
four (19%) out of 21 C. tropicalis, all six S. cerevisiae, all two P. guilliermondii and the 
only isolated C. pararugosa were resistant to Itraconazole with MICs ≥ 1 μg/ml. The 
MIC ranges of all isolates for Nystatin and Caspofungin were 1 - 8 μg/ml and 0.063 - 
0.5 μg/ml respectively. Only one C. parapsilosis isolate had a MIC of 1 μg/ml for 
Caspofungin (Figure 29). 
Non- C. albicans yeast isolates with MICs above the clinical breakpoint were not 
more prevalent in patients with recorded history of one or more exposure to 
antimycotic therapy and there were no cases of clinical OC caused by species other 
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Figure 29: In vitro susceptibility of the isolated yeast species to the different antifungal 
agents. A clinical breakpoint was not yet defined for Nystatin. All species with MICs above 
the clinical breakpoint were considered resistant (in vitro). All C. glabrata isolates were 
resistant to Itraconazole but were susceptible to Fluconazole; resistance to Itraconazole was 
further seen for the species I. orientalis, C. tropicalis, all S. cerevisiae, P. guilliermondii and 
C. pararugosa spp. I. orientalis were the only species resistant to Fluconazole. All species 






Despite the introduction of antiretroviral therapy, under which the prevalence of 
opportunistic infections has decreased (Hood et al. 1998; Schmidt-Westhausen et al. 
2000; Greenspan et al. 2004), OC still remains a significant and common 
opportunistic infection in HIV-infected individuals (Thompson et al. 2010; Mataftsi et 
al. 2011). This is especially true in Sub-Saharan Africa, where HAART is still not 
widely available (Hamza et al. 2006; Tirwomwe et al. 2007; Hamza et al. 2008). The 
prevalence of OC and the yeast species involved vary throughout the world, as well 
as within the countries themselves due to many confounding variables, such as the 
availability of HAART, access to health care, nutrition, present oral and 
environmental yeast flora. Candida albicans has been reported to be the most 
frequently isolated yeast species throughout the world. Also, the incidence of other 
Candida species less susceptible or resistant to the antifungal drugs in use has been 
increasing and has become a strong concern for clinicians in the management of 
affected individuals (Pfaller et al. 2007). Yeast identification and antifungal 
susceptibility testing have therefore become of high importance. As oral and invasive 
yeast infections are mostly caused by the endogenous colonizing yeasts of the 
mucosal surfaces (Fetter et al. 1993; Pfaller 1995; Vargas and Joly 2002; Grimoud et 
al. 2003) and the distribution as well as the pathogenicity and antifungal drug 
susceptibility of the species vary in the different geographical regions, it is important 
to investigate their prevalence and distribution throughout the world. Although 
numerous epidemiological studies in Europe and the Americas on the prevalence of 
yeasts causing candidiasis have been published, little is known about the yeast flora 
and etiology of candidiasis in people living in developing countries. In Sub-Saharan 
Africa, where the majority of HIV-infected individuals live, only few studies on the 
prevalence of yeasts in the oral cavity of HIV-positive patients (Hodgson and 
Rachanis 2002) have been performed. For Chad, even no data are available at all. 
We have therefore studied the prevalence and epidemiology of oral asymptomatic 
and symptomatic yeast carriage of HIV-positive vs. HIV-negative individuals from 
Southern Chad, identified the yeast species involved and analyzed the impact of age, 




oral yeast colonization and infection. Susceptibility of the differentiated yeast isolates 
to common antifungals was determined. 
 
Prevalence of oral candidiasis 
The overall oral Candida carriage rate (25%) as well as the prevalence of OC 
(10.2%) of HIV-positive patients found in Chad was surprisingly low as compared to 
other African countries where numbers ranged from 41.2% in Cameroon (Lohoue 
Petmy et al. 2004) to 81.5% in Ghana (Kwamin et al. 2013) and 81.3% in South 
Africa (Patel et al. 2006). These differences may be due to the selected study groups 
(e.g. HIV disease stage and availability of antiretroviral treatment). However, chosen 
diagnostic tools and criteria and experience level of the investigators may also play a 
role. In the clinic of Maingara, as it is a specialized center for HIV/AIDS patients with 
rigorous follow up and availability of HAART, cases with advanced stages of immune 
deterioration were rare.  
Many previous studies have demonstrated that potent antiretroviral treatment like 
HAART containing a combination of antiretrovirals significantly reduces opportunistic 
infections such as OC (Powderly et al. 1998; Yang et al. 2006; Lourenco et al. 2011). 
This has been found in Cameroun, were the prevalence of OC was 30% in 
HIV+/HAART+ versus 70% in HIV+/HAART- patients, as well as in Tanzania where 
values were 15% and 38%, respectively (Hamza et al. 2006; Njunda 2011). This 
improvement of oral fungal infection by HAART is as well supported by our findings. 
Although our numbers of OC prevalence (5% in HIV+/HAART+ and 16% in 
HIV+/HAART-) were far lower, they were closer to those of studies performed in 
South India (Umadevi et al. 2007) and Taiwan (Yang et al. 2006), where the 
prevalence of OC reached 8% and 24% in South India and 2.1% and 10.6% in 
Taiwan in HIV+/HAART+ and HIV+/HAART- patients, respectively. A possible 
explanation for the very low prevalence of 5% OC found in our cohort of 
HIV+/HAART+ patients might be the treatment duration. The prevalence of OC was 
significantly reduced with HAART over a period of six to twelve months and beyond. 
The same was found in a cohort of 532 HIV-positive patients recruited from the 
Muhimbili National Hospital HIV Clinic in Dar es Salaam, Tanzania (Hamza et al. 
2006) and the prospective longitudinal study of 142 HAART-treated HIV-positive 
patients in Taiwan (Yang et al. 2006). In a cohort of 92 HIV-positive patients from 




study, 53% of the patients were under HAART, 78% (n=141/180) for at least six 
months, and 54% (n=97/180) for 12 months or more. 
Fungal infection is usually caused by commensal yeast species of the mucosa (Fetter 
et al. 1993; Pfaller 1995; Vargas and Joly 2002). Therefore, another factor explaining 
our results could be the general lower prevalence of colonizing yeasts in the Chadian 
population, represented by our HIV-negative control group (22.5%). 
It may also have been possible, that among the HIV+/HAART- patients, the HIV 
infection had been only recent and therefore at an early stage, where opportunistic 
infections like OC are not yet apparent (Wanzala et al. 1989; Owotade et al. 2008).  
In many developing countries, traditional herbal medicine is still widely used, some of 
which have been shown to have an anticandidal effect (Rukayadi et al. 2008; 
Marzouk et al. 2009). Due to the poor and marginally developed health care system, 
the use of traditional herbal medicine is widely spread in Chad. However, precise 
data concerning its use were not available for this study.  
Saccharomyces cerevisiae was found to be the second (in Bemouli) and third (in 
Maingara) most common yeast species isolated among our Chadian patients without 
being a cause of infection. Potentially, these may originate from wild S. cerevisiae 
yeast strains used for the local home-brewed and widely consumed alcoholic 
beverage in Chad, known as bili-bili. Bili-bili is made by fermenting locally grown 
sorghum and millet (Maoura 2005). Oral uptake of S. cerevisiae is known to have an 
inhibitory effect on OC (Premanathan 2011).  
Although the introduction of HAART has led to a significant decrease or even 
absence of oral lesions such as OC (Powderly et al. 1998; Yang et al. 2006; Jordan 
2007; Lourenco et al. 2011), OC continues to be a significant oral lesion highly 
associated with HIV infection in both developed and developing countries 
(Ranganathan et al. 2004; Hodgson et al. 2006). Oral colonization with Candida, 
even though observed to decrease, was also still present: 9 % of our HIV+/HAART+ 
patients were asymptomatic yeast carriers, including those with mild symptoms the 
prevalence rose up to 14%. This correlated with the observations made in a study in 





Classification and epidemiology of the different clinical features of oral 
candidiasis (OC)  
Very few studies investigating on the prevalence of OC describe the observed oral 
lesions in a defined way; and most rely on presumptive rather than definite diagnosis. 
The most common used classification for oral lesions in HIV-infected patients, 
especially in developing countries, is the ECC classification (EC-Clearinghouse 
1993). In this revised classification from 1993 only two forms of OC are distinguished: 
the pseudomembranous (PC) and the erythematous candidiasis (EC). The 
description of the PC: "white or yellow spot or plaques that can be located in any part 
of the oral cavity and can be wiped off to reveal an erythematous surface which may 
bleed" (EC-Clearinghouse 1993, page 289) only fitted to five (14.3%; 5/35) of our 
HIV-positive patients with OC. The majority of our HIV-positive patients with severe 
symptoms (n=41/64; 64%; n=17/35= 48.6%) suffered from a whitish or yellowish 
coating affecting >50% of the dorsum of the tongue, which was not easily removable. 
Only 39% (n=16/41) of these patients were yeast-positive and in 94% (n=16/17) of 
the cases colonized by C. albicans. The median CD4 T cell count of these yeast-
positive patients was <150 CD4 T cells/µl, so that the manifestation of oral lesions 
strongly associated with HIV was highly suspect. Although the diagnosis of OC still 
stays essentially clinical (Coronado-Castellote and Jimenez-Soriano 2013), none of 
the criteria of the described oral lesions of the ECC classification corresponded to the 
oral manifestations seen here. The proposed classification by Axell et al. (1997) 
differentiates between an acute and a chronic type of OC, Candida-associated 
lesions and keratinized primary lesions superinfected with Candida. Of these 
variants, superinfected keratinized primary lesions like oral hairy leukoplakia or 
lychen planus with Candida could be taken into consideration, as the lesions were 
not easily to remove. Anyhow, the coating in our patients affected the dorsum of the 
tongue, which is neither usual for the oral hairy leukoplakia nor the lychen planus. 
Oral hairy leukoplakia is usually described to be found on the lateral tongue, with 
eventually vertical corrugations or a flat appearance which cannot be wiped off (EC-
Clearinghouse 1993). Lychen planus of the mouth appears as lace-like fine white 
lines usually at the inside of the cheeks (AAOMP 2005). These variants clinically 
seemed less likely. Another possible variant could be the hyperplastic plaque-like 
candidiasis. Tissue biopsy to confirm the hyperplastic form was not available and 




commisures (Akpan and Morgan 2002; Williams and Lewis 2011; Madhu 2013), 
which did also not fit to our cases. Pseudomembranous candidiasis is highly 
associated with CD4 T cells dropping <200 CD4 T cells/μl, which is in accordance 
with our study (Ranganathan et al. 2004; Mercante et al. 2006; Witzel et al. 2008; 
Bodhade et al. 2011). Our yeast-positive patients with observed whitish or yellowish 
coating of more than 50% of the tongue area, classified as nonspecific OC, had a 
median CD4 T cell count <150 cells, making a presumptive classification as 
pseudomembranous candidiasis reliable. 
The second most common clinical sign in our patients was the median rhomboid 
glossitis which affected 20.3% (n=13/64) of the patients with severe symptoms. Out 
of these, 69% (n=9/13) were yeast-positive, in eight out of nine C. albicans was 
isolated. The median rhomboid glossitis presents as a central red area with papillary 
atrophy of the dorsum of the tongue or palate. Median rhomboid glossitis has 
infrequently been described as a lesion also seen in HIV-positive patients (Gazzard 
and Smith 1990; Flaitz and Hicks 1999; Barasch et al. 2000; Okunseri et al. 2003). In 
the classification of Axell et al. it has been included and mentioned as a distinct form 
of "Candida-associated lesions" (Axell et al. 1997). In the ECC classification it is not 
mentioned. Some authors suggest it is "a form of erythematous candidiasis " 
(Kolokotronis et al. 1994; Lalla et al. 2013). Therefore, it may have been misclassified 
as erythematous candidiasis in previous studies. As outlined above, the most 
common types mentioned and discussed are the pseudomembranous and the 
erythematous candidiasis. In accordance with the description of the erythematous 
candidiasis in the ECC classification ("red areas located on the palate or dorsum of 
the tongue"), the patients in our study group which presented with the features of the 
median rhomboid glossitis could be classified as erythematous candidiasis.  
Since the erythematous candidiasis is as well described as a red atrophic area with 
loss of filiform papillae when affecting the tongue (Lalla et al. 2010), our patients with 
symptoms of tongue atrophy and positive yeast growth could as well be classified as 
erythematous candidiasis resulting in a total prevalence of 38.4% (n=10/26) of 
erythematous candidiasis in HIV+/HAART- patients. This was similar to the findings 
in a study performed among HIV+/HAART- patients in India where the prevalence 
was 39.3% (Bodhade et al. 2011).  
The epidemiology (relationship with HAART and CD4 T cell counts or other factors) 




investigated. In a cohort from Germany the erythematous candidiasis was only found 
in patients not undergoing any antiretroviral treatment (Jordan 2007). It is not clear, if 
the patients classified as erythematous candidiasis included the features of the 
median rhomboid glossitis. Anyhow, if the median rhomboid glossitis is a form of 
erythematous candidiasis, our findings would be similar to the German and Indian 
study (Jordan 2007; Bodhade et al. 2011). In studies from Kenya and South Africa 
performed before the HAART era, the erythematous candidiasis was significantly 
more prevalent than the pseudomembranous candidiasis (Hodgson and Rachanis 
2002) and in a Tanzanian study including HIV+/HAART+ patients, the prevalence of 
erythematous candidiasis was only 1.4% (Hamza et al. 2008). Therefore, a 
correlation between the appearance of erythematous candidiasis (and possibly 
median rhomboid glossitis) and the absence of HAART seems reliable, and is 
supported by our findings here, and the German and Indian study (Jordan 2007; 
Bodhade et al. 2011).  
A correlation between erythematous candidiasis and CD4 T cell counts dropping 
<400 CD4 T cells/μl has been observed (Mercante et al. 2006; Witzel et al. 2008), 
which would correlate with our findings: patients with median rhomboid glossitis had 
a median CD4 T cell count of 200 CD4 T cells/μl and those with atrophy 338 CD4 T 
cells/μl. In a study in Zambia, erythematous candidiasis was even found to be 
associated with CD4 T cell counts <200 CD4 T cells/μl (Hodgson 1997).  
According to Bodhade et al. (2011), erythematous candidiasis may as well be a good 
marker of immunosuppression, anyhow, not as sensitive and specific as the 
pseudomembranous candidiasis.  
The distribution of pseudomembranous and erythematous candidiasis among our 
patients with OC (n=34) would then be 68% and 32% respectively, which matches 
the results in a study published in India (2008), where 83.3% of the cases with OC 
had pseudomembranous type lesions followed by erythematous candidiasis with 
16.6% (Nadagir et al. 2008). The higher rate of pseudomembranous candidiasis in 
the Indian study can be explained by the fact, that the cohort consisted of terminally 
ill patients, here again underlining the high predictive value and correlation of 
pseudomembranous candidiasis with a severely deteriorated immune system 





Species prevalence and association with OC 
Worldwide, C. albicans has frequently been found to be the most prevalent yeast 
species found in the oral cavity of HIV-positive and healthy subjects ranging from 
50% in Iran (Badiee et al. 2010) to 91.5% in South Africa (Blignaut 2007). This 
species was also predominant in our study performed in Chad; with 44.2% in the 
HIV-negative control group, 58.6% in the HIV+/HAART+ group, and 87.1% in 
HIV+/HAART- patients, which matches with the findings of Nweze and Ogbonnaya 
(2011) in Nigeria.  
I. orientalis and C. tropicalis were the second most common yeast species isolated in 
the oral cavity of our HIV-positive patients, which correlates with the findings of a 
study in an HIV cohort from Nigeria (Enwuru et al. 2008) and partly with those from 
Uganda (Agwu et al. 2011). Other studies found C. glabrata at second position 
(Sanchez-Vargas et al. 2005a; Sanchez-Vargas et al. 2005b; Badiee et al. 2010). C. 
glabrata ranked only fifth in our HIV-positive patients.  
As C. glabrata has often been co-isolated with C. albicans in patients with OC its 
clinical relevance has been questioned (Dronda et al. 1996; Ally et al. 2001; Redding 
2001). In our study groups of HIV-positive patients C. glabrata and C. tropicalis were 
more frequently present as sole colonizing yeasts of the oral cavity when CD4 T cell 
counts were <200 CD4 T cells/µl. But these patients did not have any clinical signs of 
infection. Furthermore all the other non-C.albicans spp. were only associated with a 
low fungal burden, mild or no symptoms, as well as high CD4 T cell counts. This 
would underline the fact, that Candida species other than C. albicans are considered 
to be less pathogenic and may simply act as commensals (Dronda et al. 1996; Fidel 
et al. 1999).  
Although isolation of non-C. albicans yeast spp. has been reported in HIV-positive 
patients, in almost all reports, OC has been reported to be mainly linked with the 
presence of C. albicans or C. albicans mixed with a non-C. albicans yeast spp. 
(Redding 2001; Patel et al. 2006; Agwu et al. 2011). Similarly in our cases of OC, C. 
albicans was also the most prevalent yeast. Consequently, C. albicans is considered 
to be more pathogenic than other Candida species. Its putative virulence factors 
seem to be expressed in higher ratios in HIV-positive patients when the hosts 
immune system fails (De Bernardis et al. 1996; Wu et al. 1996; Fidel 2011; Cassone 




Nevertheless, C. glabrata should not be ignored as mixed infections of C. glabrata 
with C. albicans are more severe in patients with HIV infection (Redding 2001). 
Furthermore, the intrinsic resistance of C. glabrata to many azoles (Bagg et al. 2003), 
especially Fluconazole, makes co-infection due to this species more difficult to treat 
(Redding 2001).  
The increasing reports of the emergence of non-C. albicans species associated with 
OC and HIV infection (Schoofs et al. 1998; Melo et al. 2004; Enwuru et al. 2008) has 
been explained by the repeated exposure to azoles, which results in the selection of 
less susceptible species like C. glabrata or I. orientalis (Cartledge et al. 1999; Hope 
et al. 2002; Snydman 2003; Hamza et al. 2008; Agwu et al. 2011). Antifungal 
exposure was rare in our study group and patients harboring non-C. albicans yeast 
spp. did not have a history of previous fungal therapy. Therefore, the emergence of 
non-C. albicans yeast spp.in our study cannot be explained by this hypothesis. 
 
Emergence and etiology of non-C. albicans yeast species 
Besides the overall reduced rate of yeast prevalence in the oral cavity and clinical 
manifestation of OC, our study group of HIV+/HAART+ patients also displayed an 
increased species diversity, as similarly seen in a study in Brazil (Melo et al. 2004). 
Non-C. albicans yeast spp. isolated from our patients were I. orientalis, C. tropicalis, 
C. glabrata, C. parapsilosis, C. orthopsilosis, P. fabianii, P. farinosa, P. guilliermondii, 
C. kefyr, C. pelliculosa, C. rugosa, C. pararugosa and one isolate of a novel 
C. orthopsilosis-like species. It is well established that the protease inhibitors (PI) that 
may be included in HAART have an effect on colonization at least with C. albicans, 
possibly through reduction in adhesion to epithelial cells by inhibiting the secretory 
aspartic proteases (SAP) of C. albicans (Borg-von Zepelin et al. 1999; Cassone et al. 
1999; Witzel et al. 2008). The National Guidelines of the Republic of Chad, however, 
specify treatment of HIV-infected patients with a combination of the three reverse 
transcriptase inhibitors (RTI) stavudine, lamivudine, and nevirapine and patients were 
treated accordingly. Nucleoside reverse transcriptase inhibitors (NRTI) appear to 
have little in vitro effect on virulence traits of C. albicans (Ahmadou Ahidjo et al. 
2008). Although the genome of C. albicans contains several transcriptionally active 
genes with similarities to reverse transcriptase (e.g. the “zorro element” family) which 
appear to be involved in the process of filamentous growth and are lacking from most 




C. albicans yeast spp. under this particular treatment, although no particular data are 
available on interaction of these C. albicans proteins with NRTIs. Therefore, in the 
absence of PIs and antifungal treatment, the improvement of the immune function 
under HAART with increased CD4 T cell counts and decreased viral loads is likely to 
be responsible for the decrease of OC (Fethi et al. 2005; Sanchez-Vargas et al. 
2005a; Fidel 2006; Yang et al. 2006; Ortega et al. 2009; Wu et al. 2011) and the 
emergence of non-C. albicans yeast spp. colonizing the oral cavity of HIV-infected 
patients (Nweze and Ogbonnaya 2011). 
 
HIV-negative subjects also presented with lower prevalence of C. albicans and higher 
diversity of non-C. albicans yeast spp. which is similar to the reports from Hauman, 
Mc Collough, Xu and Mitchell and Pomarico (Hauman et al. 1993; McCullough 2001; 
Xu and Mitchell 2003; Pomarico et al. 2009). A review giving an overview over oral 
fungal infection in Africa showed that the resident oral yeast flora of HIV-negative 
individuals in resource-poor countries is markedly different from that in developed 
countries with non-C. albicans yeast spp. being more prevalent (Hodgson and 
Rachanis 2002). This is in agreement with our study and a report from China in 2002 
(Xu and Mitchell 2003): in healthy HIV-negative individuals from villages in China 
without antifungal history, the prevalence of C. albicans was only 9.4% compared to 
77-84% in healthy HIV-negative individuals from Hong Kong (Sedgley and 
Samaranayake 1994). Poor oral hygiene and no access to dental health care or even 
malnutrition in the studied regions may favor colonization by non-C. albicans yeast 
spp (Jabra-Rizk et al. 2001). It has been further suggested that the wider spectrum of 
yeast species observed in antifungal naive HIV-negative individuals may reflect "an 
ancestral human-yeast association" and that development factors as industrialization, 
lifestyle and regular dental health care “may have favored the selection of C. albicans 
over other species" (Xu and Mitchell 2003). This is supported by the results of a 
study performed among an indigenous population in a remote area of French South 
Guiana, where it was found that the prevalence of colonizing non-C. albicans yeast 
spp. was far higher than C. albicans (Angebault et al. 2013). The fact that C. albicans 
is more prevalent in HIV-positive patients in Africa, may be due to the fact, that C. 
albicans is more pathogenic than other Candida species and highly associated with 
infection by the HI virus (Redding 2001; Agwu et al. 2011). Furthermore as extensive 




towards non-C. albicans yeast spp. is less marked in African countries and C. 
albicans colonization more prevalent. 
 
Candida dubliniensis: an HIV-associated species? 
C. dubliniensis has repeatedly been reported to be highly prevalent in HIV-infected 
patients (Paugam et al. 2008). We did not find a single isolate of this species among 
our patients. However, most of the studies in which C. dubliniensis has been found 
have been conducted outside of the African continent (Sullivan et al. 1995; Binolfi et 
al. 2005; Loreto et al. 2010; Wu et al. 2011) and studies performed on the African 
continent in Tanzania, Uganda and Nigeria showed the same phenomenon like in our 
investigation (Enwuru et al. 2008; Hamza et al. 2008; Agwu et al. 2011). Technically, 
the absence of C. dubliniensis may have been due to the media we used for initial 
culture, where C. dubliniensis could not be discriminated from C. albicans and a 
lower number of C. dubliniensis colonies may have gone unnoticed. However, the 
absence of C. dubliniensis is in line with the hypothesis, that Africans may be less 
susceptible to colonization or infection with this species as shown in an South African 
cohort (Blignaut et al. 2003).  
Under Fluconazole therapy, C. albicans may be replaced by C. dubliniensis (Martinez 
et al. 2002) as a colonizer of the oral cavity. This is supported by a study performed 
in India among terminally ill and patients not responding to Fluconazole therapy, 
where C. dubliniensis was the second most prevalent fungal species after C. albicans 
(Nadagir et al. 2008). Most of these subjects had been exposed to prolonged 
Fluconazole therapy. A rare practice of antifungal drug prophylaxis or extensive 
exposure to azoles in developing countries might be another explanation for the 
absence or very low prevalence (Hamza et al. 2008; Kwamin et al. 2013) of C. 
dubliniensis in low-resource settings.  
In further contrast, C. dubliniensis has also been found to be more prevalent among 
HIV-negative subjects in studies in Tunesia (Khlif et al. 2009) and Brazil (Back-Brito 
et al. 2009) and in South African White healthy individuals (Blignaut et al. 2003) than 
in HIV-positive subjects. The epidemiology of this new species is therefore so far not 





Oral fungal burden and OC 
A high fungal burden was highly associated with the presentation of severe 
symptoms, colonization with the species C. albicans and CD4 T cell counts <200 
CD4 T cells/μl irrespectively of HAART. These findings were comparable with the 
ones found in a study evaluating the clinical oral state of patients with the quantitative 
growth of C. albicans; patients with OC had higher CFU counts than Candida carriers 
although CFU counts in that study were counted from saliva (Epstein et al. 1980). 
Similarly, in a recent study from South Africa, high oral Candida CFU correlated with 
low CD4 T cell counts in HAART+ patients (Owotade et al. 2013). Patients with mild 
symptoms, defined as whitish or yellowish coating of the dorsum of the tongue <50% 
of the area, were less likely to be yeast-positive and if yeast-positive, the number of 
CFU counts was very low. This would emphasize that our patients classified with mild 
symptoms and a positive yeast culture were less suspect to suffer from OC, but were 
more likely to be colonized only. 
Independently of the CFU counts and irrespectively of HAART, OC, especially with 
the features of the pseudomembranous candidiasis, was highly associated with CD4 
T cell counts <200 CD4 T cells/µl and the isolation of C. albicans. This was not 
always as conclusive in patients with mild symptoms. As shown in several studies 
conducted in Tanzania (Matee et al. 2000), Ghana (Kwamin et al. 2013) and India 
(Lattif et al. 2004; Mane et al. 2010; Anwar Khan 2012), OC was highly associated 
with CD4 T cell counts <200 CD4 T cells/µl and as shown in a study in Brazil (Witzel 
et al. 2008) with isolation of C. albicans.  
All our patients with severe symptoms and positive yeast growth were colonized by 
C. albicans, except for one case: here, the patient was colonized by P. fabianii and 
had the clinical features of the median rhomboid glossitis. The patient was 
HIV+/HAART- and had a CD4 T cell count of 495 CD4 T cells/µl. Median rhomboid 
glossitis is an HIV associated lesion and the patient had high oral fungal burden; 
nevertheless, we would rather suggest an oral yeast colonization in that case as P. 
fabianii is not common in causing infection (Dabas 2013). Although erythematous 
candidiasis may as well be a good marker of immunosuppression as postulated by 
Bodhade et al. (2011), it is not as sensitive and specific as the pseudomembranous 
candidiasis (Patton 2000). Nevertheless, when HIV-positive subjects present with 




therapy failure in HIV+/HAART+ patients with a dropping CD4 T cell count <200 CD4 
T cells/µl should be suspected, especially when CD4 T cell counts are not available.  
In the majority, OC can be diagnosed by the clinical appearance itself, but in 
HIV+/HAART+ patients, the clinical impression of white coating on the tongue giving 
suspicion of OC may be misleading. In our study, in almost 60% of our 
HIV+/HAART+ patients with severe symptoms no yeasts were found in the oral 
cavity, indicating, that antifungal treatment was not necessary. Therefore, analysis of 
further symptoms, like burning sensation, cotton taste, swallowing pain as well as the 
microbiologic diagnosis leading to the identification of Candida can help to identify 
patients in need of antifungal or antiretroviral treatment.  
For HIV+/HAART- patients with severe symptoms, the probability of OC was higher. 
Here, 60 % of our HIV+/HAART- patients with severe symptoms were yeast-positive, 
had a mean CD4 T cell count <200 CD4 T cells/µl and were mainly colonized with C. 
albicans. Anyhow, HIV+/HAART- patients may be severely immunocompromised 
without presenting any clinically visible lesions. Here, 14% were asymptomatic yeast 
carriers of which more than 50% had CD4 T cell counts <200 CD4 T cells/µl. 
 
Impact of age and gender 
Although a significant age influence on oral yeast colonization and infection could not 
be shown here, a tendency towards higher colonization rate with rising age and drop 
again after the age of 45 could be observed in both, HIV+/HAART- and HIV-negative 
subjects. This phenomenon has also been reported in Jordanian patients 
(Rawashdeh et al. 2011). In HIV+/HAART+ patients the observation was reverse. 
The younger group of patients aged from 18-25, which also was the group being 
sexually more active at highest risk for the HIV infection, had the highest prevalence 
of positive yeast growth. With rising age the yeast prevalence was decreasing, also 
correlating with the duration of HAART.  
We did not find any significant differences according to the gender, only that the oral 
fungal burden was higher in male than in female patients. Alcohol consumption and 
smoking, which may influence oral candidal colonization and overgrowth 
(Nittayananta et al. 2001; Petruzzi et al. 2013), is more common among men; this 
fact and that HIV-infected male patients would only present themselves at the HIV 
health care center in a more advanced stage of the disease, thus have more severe 




a study among HIV-positive patients in Thailand, men were also significantly more 
likely to have oral lesions than women (Nittayananta et al. 2001). 
 
Susceptibility and effectivity of antifungal treatment 
In our setting, a basic selection of drugs was available to treat and prevent the most 
common AIDS-related opportunistic diseases, including a limited supply of 
antimycotics. During the study period, several patients were treated with antimycotics 
(oral Nystatin, Ketoconazole, or Fluconazole). All patients with severe symptoms and 
positive yeast carriage treated during the study period and seen for a follow-up were 
yeast free after treatment, including those under Fluconazole prophylaxis, confirming 
the absence of clinically resistant species. The observed effectivity of antifungal 
treatment seen in patients with severe symptoms treated during the study period was 
reflected in the in vitro susceptibility testing. All C. albicans isolates were susceptible 
to the antifungals tested. Decreased susceptibility was seen within the epidemiologic 
cut-offs for intrinsic resistance to azoles in C. glabrata, C. tropicalis and I. orientalis 
especially for Itraconazole (Pfaller et al. 2006). Otherwise, all the species were 
susceptible for Fluconazole, except for I. orientalis. That more species were resistant 
to Itraconazole may be due to the fact that Ketokonazole, which has a closer 
structural topology to Itraconazole, had been more available than Fluconazole in the 
clinic. Increased MIC values towards Caspofungin were determined for species of the 
C. parapsilosis complex, as also described previously (Badiee et al. 2010). Azole 
exposure has previously been described to lead to a shift in the pattern of colonizing 
yeast species towards less susceptible species like C. glabrata or I. orientalis 
(Cartledge et al. 1999; Hope et al. 2002; Snydman 2003; Hamza et al. 2008; Agwu et 
al. 2011). However, all of our patients harboring C. glabrata or I. orientalis had no 
previous history of antifungal treatment. A relationship between antifungal treatment 
and emergence of non-C. albicans yeast spp. was therefore not apparent among the 
patients from Chad, but rather a correlation with antiretroviral therapy and higher CD4 





The study was performed to determine the prevalence and epidemiology of oral 
candidiasis among HIV-positive patients in Chad and evaluate the susceptibility of 
the yeasts found in the oral cavity to five antifungals. 
The prevalence of oral candidiasis (10.2%) and colonization (25.4%) among HIV-
positive patients in the studied area of Chad was surprisingly low. Several factors 
may have contributed to this result: (i) the fact that it was a specialized center with a 
high coverage of HAART and eventually a high prevalence of patients in early stages 
of HIV infection, (ii) a general low colonization rate among the population and (iii) use 
of medicinal plants or beverages which may have some antimicrobial effect. 
The main types of oral candidiasis seen were an atypical type of pseudomembranous 
candidiasis and the median rhomboid glossitis. Last type was mainly seen in 
HIV+/HAART- patients. High fungal burden was highly associated with oral 
candidiasis, CD4 T cell counts <200 CD4 T cells/µl and the presence of C. albicans. 
There were no cases of oral candidiasis caused by non-C. albicans yeast spp. 
Candida albicans was the predominant species found in all subgroups with the 
highest prevalence in HIV+/HAART- patients. HIV-negative as well as HIV+/HAART+ 
patients had a higher yeast species diversity, but no C. dubliniensis was found. 
HAART significantly reduced the rate of oral candidiasis and colonization with yeasts, 
and was associated with a shift towards non-C. albicans yeast spp. correlating with 
the duration of HAART. 
Clinically, neither antifungal drug resistance nor therapy refractory cases were found, 
but higher MICs for azoles in the species C. glabrata, I. orientalis and C. tropicalis 
were present. The emergence of non-C. albicans yeast spp. was not associated with 
antifungal treatment, but was rather the result of a recovered immune system under 
extended HAART with a rise in CD4 T cell counts.  
In conclusion, our results suggest that (i) severe oral lesions as oral candidiasis are 
strong markers of immunodeficiency and may be used to evaluate the patient's 
immune status and guide therapy, (ii) oral candidiasis is associated with the species 
Candida albicans, (iii) antifungal resistance and infection caused by non-C. albicans 
yeast spp. is not yet a point of concern in Chad; Fluconazole may be continued to be 















6.2 Informed consent document 
 
Ville / Jour / Mois / Année 
………. /………. / ........... /………. 
 
OBJET : Accord écrit pour le projet « Infection de la muqueuse orale chez des 
patients atteints par le virus du SIDA » 
 
Je soussigné (e), Nom: …………………………………………………. 
Prénom: ………………………………………………….......................... 
Sexe : ………………………………………………….............................. 
Age: …………………………………………………................................. 
Nationalité : ………………………………………………........................ 
Adresse : …………………………………………………........................ 
  
déclare participer de mon plein gré (sans contrainte d’une tierce personne) à l’étude 
concernant l’apparition de la colonisation de la muqueuse orale par le champignon 
de levure « Candida albicans » et l’évaluation de sa prévalence en rapport avec 
l’infection par le virus du SIDA. 
Je suis bel et bien informé (e) que cette étude à laquelle je participe est une étude 
simplement descriptive qui n’intervient en aucun cas dans le traitement standard 
pratiqué à l’hôpital. 
D’autre part, il m’a été certifié que le médecin en charge me fera un prélèvement 
buccal avec un bâtonnet enroulé du coton. Quant au traitement standard appliqué à 
l’hôpital, il restera le même. Après une période d’observation, dont la durée sera 
fixée par le médecin, le (la) patient (e) que je suis, devra se présenter de nouveau 
pour un deuxième prélèvement buccal. 
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